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Two cellular reprogramming technologies have emerged that demonstrate 
that cell-fate can be converted by ectopic expression of defined transcription 
factors: induced pluripotent stem (iPS) cell technology and induced neuronal (iN) 
cell technology.  These recent advances in cell reprogramming strategies have 
great potential utility for patient-specific disease modeling and for applications in 
regenerative medicine. Current models of neurodegenerative diseases are 
limited in their representation of disease phenotypes and there is an essential 
need for human cellular models of neurodegenerative disorders.  Induced 
pluripotent stem (iPS) cell technology offers a two-step approach to disease 
modeling, in which patient somatic cells are first reprogrammed to a pluripotent 
state and subsequently differentiated in neurons.  In contrast, induced neuronal 
(iN) cell technology allows for the direct conversion of somatic cells to neurons. 
Here I demonstrate the modeling of Alzheimer’s disease (AD) using both iPS and 
iN cellular reprogramming technologies.  These bioengineered human cell-based 
models of AD provide unique and invaluable tools for elucidating the mechanism 
of AD pathogenesis. 
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Chapter 1. A. Clinical, genetic, and molecular characteristics of Alzheimer’s 
disease  (AD) 
 
Clinical Phenotype and Pathology  
AD is the most common cause of dementia in the elderly (>65 years), 
accounting for 60-70% of all dementia cases; an estimated 26 million people are 
affected worldwide and this number is predicted to quadruple by 2050 (Daffner, 
2010).  AD is a neurodegenerative disorder clinically characterized by 
progressive cognitive decline.  During early stages of the disease, short-term 
(episodic) memory decline is prominent.  Disease progression results in further 
impairment of cognitive functions, including spatial orientation, reasoning and 
judgment, language skills, and emotional affect (Alzheimer et al., 1995).  The 
major risk factor for AD is age; risk doubles every five years after the age of 65 
(Brookmeyer et al., 1998).  The prognosis for AD is poor, as there is presently no 
cure for AD; current therapies are only symptomatic and do not treat the 
underlying disease process (Daffner, 2010).  The median survival after initial 
diagnosis is between five and ten years (Walsh et al., 1990).  
The definitive diagnosis of AD requires post-mortem detection of two 
hallmark protein aggregate lesions: extracellular amyloid plaques and 
intracellular neurofibrillary tangles (NFTs), found most prominently in cortical and 
subcortical areas of the medial temporal lobe, including the hippocampal 
formation and amygdala (Alzheimer et al., 1995). The major proteinaceous 
component of amyloid plaques is the amyloid-β (Aβ) peptide, derived from 
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proteolytic cleavage of the amyloid precursor protein (APP).  The length of Aβ 
peptide can vary from 39-43 residues; the 40-amino acid variant (Aβ40) is most 
common whereas the 42 amino-acid variant (Aβ42) is the more neurotoxic 
species, due to its propensity to aggregate into oligomers and fibrils (Glenner and 
Wong, 1984; Masters et al., 1985).  Two varieties of amyloid plaques exist; 
diffuse plaques are comprised mainly of Aβ42 and few dystrophic axons and 
dendrites whereas dense-cored neuritic plaques are comprised of a dense Aβ42 
core, Aβ40 and other proteinaceous components such as ubiquitin and alpha-
synuclein, all surrounded by dystrophic neurites.  Dense-cored plaques are more 
prevalent in the AD brain (Glenner and Wong, 1984) (Figure 1A). 
Neurofibrillary tangles (NFTs) are filamentous inclusions composed of 
hyperphosphorylated microtubule associated protein tau (MAPT) forming paired 
helical filaments, found in neuronal cell bodies and apical dendrites.  Additionally, 
tau protein is found in distal dendrites as neuropil threads and in the dystrophic 
neurites associated with dense-cored neuritic plaques (Selkoe, 1991).  Within the 
AD brain, neurofibrillary lesions develop in a predictable pattern, providing a 
basis for distinguishing six stages of disease progression.  Braak stages I-II with 
transentorhinal lesions signify the clinically silent stage; Braak stages III-IV with 
limbic lesions indicate early stage AD; Braak stages V-VI with neocortical lesions 
signify late stage AD (Braak and Braak, 1991).  NFTs are also seen in other 
neurodegenerative disorders, including frontal temporal dementia with 
Parkinsonism linked to chromosome 17 (FTDP-17), Pick’s disease, progressive 
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supranuclear palsy (PSP), and corticobasal degeneration (CBD) (Grundke-Iqbal 
et al., 1986; Goedert et al., 1988).   
In addition to extracellular amyloid plaques and intracellular neurofibrillary 
tangles, the AD brain is further characterized by neuronal cell loss, loss of 
synapses and dendritic spines.  Additionally, there is depletion of the 
acetylcholine neurotransmitter system (Khachaturian, 1985; Selkoe, 2002). 
 
Proposed Genetic Mechanism  
PSEN1, PSEN2, and APP mutations underlie FAD 
The etiology of AD is complex, involving an interplay between 
environmental and genetic factors.  At the genetic level, there are two forms of 
AD, familial and sporadic, which nevertheless share the same clinical and 
histopathological features.  Comprising less than 1% of AD cases, familial AD 
(FAD) exhibits a Mendelian inheritance pattern and typically shows early-onset of 
clinical symptoms (<65 years) (Goate et al., 1991).  FAD is caused by autosomal 
dominant mutations in genes encoding amyloid precursor protein (APP), which 
account for about 2-3% of FAD cases (Goate et al., 1991), presenilin 1 (PSEN1), 
which account for about 70-80% of FAD cases (Sherrington et al., 1995; Cruts et 
al., 1998), and presenilin 2 (PSEN2) (Rogaev et al., 1995).  The remaining cases 
of AD are idiopathic or sporadic (SAD) (Delacourte et al., 2002). The onset of 
symptoms in SAD is typically after 65 years of age.  Although SAD is not caused 
by particular genetic mutations, a few susceptibility genes have been identified in 
SAD, including apolipoprotein E (ApoE) (Bertram and Tanzi, 2005), clusterin 
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(CLU), phosphatidylinositol-binding clathrin assembly protein (PICALM), and 
complement component (3b/4b) receptor 1 (CR1) (Lambert et al., 2009; Harold et 
al., 2009; Jun et al., 2010).  Inheritance of the epsilon 4 allele of apolipoprotein E 
(ApoE4) increases the risk for SAD (Bertram et al., 2008). 
Over twenty APP mutations have been linked to FAD including the 
Swedish mutation APP K670D/M671L (Mullan et al., 1992), London mutation 
APP V717I (Goate et al., 1991), Arctic mutation APP E693G (Nilsberth et al., 
2001) and Indiana mutation APP V717F (Murrell et al., 1991).  APP is a type-1 
integral transmembrane protein consisting of 695-770 residues.  The APP gene 
undergoes alternate splicing; APP695, APP751, and APP770 are the most 
prevalent isoforms.  APP695 is mostly expressed in neurons and lack the Kunitz-
type serine protease domain, which is found in APP751 and APP770.  The APP 
holoprotein contains the Aβ domain, which spans the transmembrane region of 
the protein  (Kang et al., 1987).  The functional significance of the APP 
holoprotein remains to be determined as mouse models show only minor 
neurological impairments (Muller et al., 1994; Zheng et al., 1995).  Rather than 
mutations in the APP gene itself, the majority of FAD cases are caused by 
missense mutations in the presenilin genes (Hardy et al., 1997; Van 
Broeckhoven et al., 1992; Levy-Lahad et al., 1995).  To date, over 130 PSEN1 
and PSEN2 mutations have been linked to FAD, including PSEN1 A246E and 
PSEN2 N141I (Sherrington et al., 1995; Levy-Lahad et al., 1995; Jayadev et al., 
2010).  The presenilins form the catalytic core of the enzyme complex γ-
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secretase (Wolfe, 2006), which, together with β-secretase, generates Aβ via 
proteolytic cleavage of the APP holoprotein. 
 
FAD mutations affect APP processing 
APP is processed by one of two pathways; the non-amyloidogenic 
pathway involves sequential cleavage of APP by the membrane-associated 
metalloprotease α-secretase and γ-secretase whereas the amyloidogenic 
pathway involves sequential cleavage of APP by the β-site APP-cleaving enzyme 
(BACE1) and γ-secretase; the latter activity generates the Aβ40 and Aβ42 
peptides.  In the non-amyloidogenic pathway, cleavage of APP by α-secretase 
activity occurs within the Aβ domain, thereby precluding formation of Aβ peptide.  
Alpha-secretase activity releases a soluble extracellular N-terminal fragment, 
sAPPα, and a C-terminal fragment, C83.  C83 can further be cleaved by γ-
secretase, generating the P3 peptide (P3 can be found in diffuse amyloid 
plaques) and the APP intracellular domain (AICD).   In the amyloidogenic 
pathway, APP cleavage by BACE1 β-secretase results in the release of a soluble 
extracellular N-terminal fragment, sAPPβ, and the C-terminal fragment, C99, 
which is further cleaved by γ-secretase to form the Aβ peptide and AICD.  While 
β-secretase activity generates the amino terminus of Aβ, cleavage by γ-
secretase dictates the length of the Aβ peptide, with Aβ40 being the most 
common species and Aβ42 being the less common but more amyloidogenic and 
neurotoxic species (Vassar et al., 1999; Edbauer et al., 2003; LaFerla et al., 
2007) (Figure 1B). 
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The mutations in APP, PSEN1 and PSEN2 that underlie FAD all affect 
APP processing and Aβ production.  FAD mutations cause either increased 
production of Aβ or the preferential increase of the more neurotoxic Aβ42 
isoform.  Some APP mutations, including the Swedish mutation, cluster around 
the β-secretase cleavage site and cause APP to be preferentially metabolized by 
β-secretase, leading to an overall increase in the production of Aβ fragments 
(Haass et al., 1995).  Other APP mutations, such as the Arctic and London 
mutations, occur in key amino acids within the transmembrane domain or around 
the γ-secretase cleavage site, altering the specificity of γ-secretase and resulting 
in the production of a higher ratio of Aβ42 to Aβ40 fragments (Suzuki et al., 1994; 
Lichtenthaler et al., 1997).  This preferential accumulation of Aβ42 peptides 
relative to the Aβ40 species is also a consequence of all presenilin mutations, 
which alter γ-secretase activity and directly affect APP processing to cause an 
increase in the production of Aβ42 over Aβ40 (Haass and Selkoe; 1998).  Indeed 
an increased Aβ42:Aβ40 ratio is the key molecular feature of AD (Hardy, 1997; 
Hardy and Selkoe, 2002). 
 
The amyloid cascade hypothesis – a prevailing theory for AD pathogenesis 
First proposed by Hardy and Higgins in 1992, the amyloid cascade 
hypothesis postulates that Aβ is the initiator of AD pathogenesis and that all other 
pathological features of AD, including tau pathology and neuronal loss, are a 
downstream consequence of Aβ accumulation, and in particular, Aβ42 (Hardy 
and Selkoe, 2002).  The pathogenic Aβ42 fragment is generated by the altered 
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cleavage of APP by β-secretase and γ-secretase.  Under this hypothesis, the 
same pathophysiological mechanism manifests in both FAD and SAD.  
Consistent with this hypothesis, all known FAD mutations cause an increase in 
Aβ accumulation, and in most cases, preferential accumulation of the Aβ42 
isoform relative to the Aβ40 isoform. However, it is important to note that the 
amyloid hypothesis is not universally accepted; opponents of this hypothesis 
propose that Aβ accumulation may be an epiphenomenon while the initiating 
pathophysiological culprit lies upstream.  
 
Mouse Models of Alzheimer’s Disease 
APP and PSEN Mouse Models 
Recapitulation of amyloid plaque pathology 
The first mouse models shown to recapitulate amyloid plaque pathology 
were generated by transgenic overexpression of human APP mutations.  These 
mouse models developed amyloid pathology in an age-dependent manner.  In 
1995, Games et al. reported the PDAPP mouse model, generated by 
overexpression of the Indiana mutation APP V717F (Games et al., 1995). In 
these mice, the APP V717F mutation caused a selective increase in Aβ42 
production and robust amyloid plaque pathology developed by six to nine months 
of age, with most plaques being diffuse.  Plaque pathology was accompanied by 
age-dependent synaptic loss (Games et al., 1995). Subsequently, in 1996, Hsiao 
et al., reported the Tg2576 mouse model, which overexpressed the cDNA of 
human APP carrying the Swedish mutation K670M/N671L (APPswe) (Hsiao et 
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al., 1996). The APPswe mutation increased the production of both Aβ40 and 
Aβ42, and amyloid plaque pathology developed in an age-dependent manner.  
Most of the plaques were dense-cored plaques and few were diffuse.  
Additionally, these mice were shown to have memory deficits.  PDAPP and 
Tg2576 mice demonstrated that altered Aβ42 to Aβ40 ratio affects the location 
plaque deposition and the particular type of plaque that is preferentially produced 
(dense-cored vs. diffuse).   Beyond PDAPP and Tg2576 mice, various other 
mouse models that express mutant human APP have been generated that also 
develop amyloid pathology and cognitive deficits (Chishti et al., 2001; Janus et 
al., 2001; Mucke et al., 2000). 
Despite accounting for the overwhelming majority of FAD cases, PSEN 
mutant mice failed to exhibit overt plaque pathology.  Mice carrying mutations in 
PSEN1 M146V or PSEN1 M146L showed selective elevation of Aβ42.  However, 
crossing PSEN1 mutant mice with APP mutant mice resulted in enhanced 
amyloid pathology.  The increase in Aβ42 production mediated by PSEN1 
mutations resulted in acceleration of amyloid deposition (Duff et al., 1996; 
Borchelt et al., 1997; Holcomb et al., 1998). APP and PSAPP transgenic mice 
exhibited amyloid plaques, including both diffuse and dense-cored plaques, that 
are structurally and biochemically similar to those found in the AD brain (Games 
et al., 1995; Hsiao et al., 1996; Borchelt et al., 1997; Holcomb et al., 1998).    
Memory decline and soluble Aβ 
Despite showing no significant neuronal loss, multiple lines of APP and 
PSAPP transgenic mice have been shown to exhibit cognitive deficits in various 
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behavioral tests, including the Morris water maze test (Hsiao et al., 1996; 
Westerman et al., 2002; Chen et al., 2000; Janus et al., 2000; Morgan et al., 
2000), strongly suggesting that cognitive decline in AD may not be due solely to 
neuronal loss.  Indeed, Morris water maze studies in PDAPP, PSAPP and 
TgCRND8 (which express both APP Swedish and Indiana mutations) mouse 
models have shown that spatial reference memory deficits correlates with levels 
of insoluble Aβ aggregates (Chen et al., 2000; Janus et al., 2000; Morgan et al., 
2000; Gordon et al., 2001).  Furthermore, analysis of age-dependent memory 
loss in Tg2576 suggests that the real correlate to memory deficits may be a 
soluble Aβ species.  In initial studies, Westerman et al., showed that spatial 
reference memory deficits developed progressively from 6 months of age and 
this decline corresponded with the development of detergent-insoluble Aβ 
aggregates. (Westerman et al., 2002).  However, while this correlation was seen 
within stratified age groups, it was not observed in a combined group of old and 
young mice.  Theses results were interpreted to indicate that insoluble Aβ is a 
surrogate marker for small soluble assemblies of Aβ that are intermediaries in the 
formation of insoluble Aβ (Westerman et al., 2002). 
This correlation between soluble Aβ and  memory decline was further 
examined in anti-Aβ immunization studies in APP and PSAPP mouse models.  
These studies demonstrated that active or passive immunotherapy resulted in 
the reversal of memory deficits in APP and PSAPP mice, despite little effect on 
clearing pre-existing plaque pathology (Janus et al., 2000; Morgan et al., 2000; 
Kotilinek et al., 2002; Dodart et al., 2002).  
	   10	  
Synaptic degeneration and amyloid plaques  
Multiple APP and PSAPP mice have demonstrated synaptic degeneration 
and dysfunction that occurs after significant amyloid plaque deposition (Irizarry et 
al., 1997; Takeuchi et al., 2000).  In addition to plaque-dependent synaptic loss 
reported in Tg2576 and PSAPP mice (Spires et al., 2005; Tsai et al., 2004), there 
is also evidence for plaque-independent synaptotoxicity. Mucke et al. have 
demonstrated that the density of pre-synaptic terminals inversely correlates with 
levels of Aβ but not APP or amyloid plaque load (Mucke et al., 2000).  
Furthermore, Buttini et al. have shown that active or passive Aβ immunotherapy 
hinders progression of age-dependent synaptic deficits in PDAPP mice (Games 
et al., 1995; Buttini et al., 2005).  This study demonstrated that the loss of 
synapses is also linked to a toxic Aβ species.   
 
Limitations of APP and PSEN models 
Despite their high Aβ levels and robust recapitulation of amyloid plaque 
pathology, APP and PSAPP mouse models suffer from substantial limitations.  
Neither APP nor PSAPP mouse models develop substantial neuronal loss 
(although APP23 mice, which express APPswe under control of the Thy1 
promoter do show limited neuronal loss in the CA1 region of the hippocampus 
(Sturchler-Pierrat et al., 1997; Calhoun et al., 1998; Calhoun et al., 1999)) 
(Irizarry et al., 1997a; Irizarry et al., 1997b).  Moreover, NFT pathology, one of 
the two hallmark lesions of AD, is absent in these mice.   
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MAPT Mouse Models  
Despite NFTs being a hallmark lesion in the AD brain, mutations in MAPT 
have not been linked to FAD.  However, mutations in MAPT are found in patients 
with frontotemporal dementia with parkinsonism linked to chromosome 17 
(FTDP-17) (Hutton et al., 1998; Poorkaj et al., 1998), demonstrating that tau 
dysfunction can lead to neurodegeneration and dementia.  
 
Recapitulation of neurofibrillary tangle pathology 
The transgenic mouse model rTg4510, which expresses mutant human 
MAPT P301L, a mutation that is linked to FTDP-1 (Hutton et al., 1998; Poorkaj et 
al., 1998) develop robust neurofibrillary pathology and exhibit significant neuronal 
loss in AD-related cortical and limbic structures (Ramsden et al., 2005).  
Furthermore, NFT pathology and neuronal loss correlates with spatial reference 
memory deficits.  These mice, however, do not develop amyloid pathology.  
Nonetheless, this and other MAPT transgenic models demonstrate that 
neurofibrillary pathology and neurodegeneration are closely related, consistent 
with the correlation between NFT pathology and disease progression (Braak and 
Braak, 1991). 
 
Neurodegeneration, memory loss and soluble Tau species 
 In the inducible rTg4510 mouse model, the onset of memory decline 
preceded significant NFT accumulation and neuronal loss.  Suppression of the 
inducible transgene with doxycycline treatment after NFT formation has occurred 
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did not affect the progression of NFT formation.  However, transgene 
suppression inhibited neuronal loss and allowed for partial recovery of spatial 
reference memory (Ramsden et al., 2005).  These findings suggest that NFT 
formation may not be directly responsible for neuronal loss and memory decline.  
Rather, an intermediate Tau species may be the mediator of toxicity.  These 
findings parallel the findings in APP mice that a soluble Aβ species rather than 
insoluble Aβ underlies memory loss (Ramsden et al., 2005). 
 
Interaction between Aβ and Tau 
Extensive AD pathology has been modeled in a triple-transgenic mouse 
model (3xTg-AD) that harbors three mutant transgenes: PSEN1 M146V, APPswe 
and MAPT P301L (Oddo et al., 2003).  These mice show an accumulation of 
intraneuronal Aβ and develop amyloid plaques, neurofibrillary tangles, synaptic 
dysfunction and memory deficits in an age-dependent manner.  Synaptic 
dysfunction and memory deficits were shown to correlate with the accumulation 
of intraneuronal Aβ. Interestingly, the memory deficits in these mice correlate 
with intraneuronal Aβ rather than plaque load, as seen in studies using Tg2576 
mice (Billings et al., 2005). 
The 3xTg-AD mouse model, and other models combining APP and MAPT 
mutations (Gotz et al., 2001; Lewis et al., 2001) demonstrate that Aβ and tau 
interaction is important in the pathogenesis of AD.  Mouse models show that Aβ 
can promote tau pathology.  Furthermore, an interplay between APP, presenilin 
and tau may underlie the disease process of AD. 
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Mouse Models are Insufficient for Modeling AD 
While transgenic models of AD have been invaluable tools for 
understanding the pathophysiological mechanism underlying AD, they fail to fully 
recapitulate the disease phenotype.  Although FAD is linked to mutations in APP 
and PSEN, mutant mice harboring FAD mutations show limited representation of 
the disease profile.  APP mice exhibit only several features of AD, including 
amyloid plaque formation, synaptic degeneration and memory decline.  
Additionally, despite accounting for the overwhelming majority of FAD cases, 
PSEN mutant mice exhibit only the accumulation of Aβ42.  While the 3xTg-AD 
mouse model recapitulates many aspects of AD, including NFT pathology, 
amyloid plaque formation, synaptic deficits and memory decline,  MAPT 
mutations are not linked to FAD.  Furthermore, that this aggressive genetic 
approach was necessary to recapitulate salient features of AD speaks to the 
complexity of modeling AD in mice and more importantly, the limitation of the 
mouse system for modeling this human disease (that involves higher cognitive 
function and occurs late in life). 
Moreover, while FAD mutations have provided a genetic signature to 
model AD, it remains that FAD represents less than 1% of all AD cases.  The 
majority of AD cases are sporadic, with no known genetic links, although studies 
have identified susceptibility genes,  including ApoE.  As such, further strategies 
are needed for modeling AD. 
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Figure 1. (A) Amyloid beta (Aβ) Plaques and Neurofibrillary Tangles in the AD 
brain.  (top panel) A representative micrograph of amyloid plaques in the AD 
brain.  Plaques were visualized by immunostaining with an antibody specific to 
Aβ42. (bottom panel) A representative micrograph of neurofibrillary tangles.  
Tangles were visualized by immunostainig with an antibody specific to paired 
helical filament. (adapted from LaFerla and Oddo, 2005)   
(B) APP Processing. Non-amyloidogenic APP processing: α-secretase 
mediated processing cleaves APP within the Aβ domain to produce secreted 
sAPPα and the non-amyloidogenic C-terminal fragment C83.  C83 can 
undergo further processing mediated by ϒ-secretase cleavage at the C-
terminal end of the Aβ domain to yield non-amyloidogenic P3.  Amyloidogenic 
APP processing: β-secretase cleaves at the N-terminal end of the Aβ domain 
to produce secreted sAPPβ and the amyloidogenic C99 fragment.  Subsquent 
ϒ-secretase cleavage of C99 at the N-terminal end of the Aβ domain gives 
rise to amylodogenic Aβ. (adapted from Crouch et al., 2008)           . 
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Chapter1. B. Reprogramming technologies and cell-based modeling of 
diseases 
 
Somatic cell nuclear transfer (SCNT) and embryonic stem (ES) cell fusion 
Nuclear reprogramming involves epigenetic changes   
Cellular differentiation is the process whereby pluripotent cells acquire a 
mature identity.  The molecular mechanism for this cell-type specification 
involves epigenetic changes to the cellular genome that dictate specific gene 
expression patterns and provide a signature for cell identity and function 
(Bernstein et al., 2007; Meissner et al., 2008).  These epigenetic changes include 
DNA methylation and histone modifications.  DNA methylation is important in the 
regulation of gene expression and silencing of repetitive elements in the genome 
(Wolffe et al., 1999; Jaenisch et al., 2003).  Histone modifications include 
acetylation, methylation, and phosphorylation.  Typically, histone acetylation 
results in gene activation and histone deacetylation results in gene repression 
(Hebbes et al., 1988; Schultz et al., 1999). 
It was previously thought that epigenetic modifications during cellular 
differentiation were irreversible and that once a cell acquires a mature identity, no 
further change in cell fate would be possible.  However nuclear reprogramming 
strategies, including somatic cell nuclear transfer (SCNT) and ES cell fusion 
experiments have proven that epigenetic modifications to the genome during 
cellular differentiation can be erased and that somatic cells can be 
reprogrammed to a pluripotent state.  The process of reprogramming the nucleus 
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of a somatic cell into an embryonic state requires removal of epigenetic changes 
in the genome acquired during the course of cell differentiation so that a new set 
of epigenetic marks for pluripotency can be established.  This involves 
inactivation of the somatic cell’s gene expression pattern and activation of the 
gene expression pattern for pluripotent cells (Reik et al., 2001; Rideout et al., 
2001). 
 
Somatic Cell Nuclear Transfer (SCNT) and ES cell fusion experiments 
Nuclear reprogramming by SCNT involves the transfer of a somatic cell 
nucleus into an enucleated oocyte, resulting in an embryo with the same genetic 
information as the donor nucleus (except for mitochondrial genes, which are 
maternally inherited) (Hochedlinger and Jaenisch, 2006; Pickering et al., 2005).  
The first successful nuclear transfer experiments were demonstrated in 
amphibians.  In 1952, Briggs and King generated normal swimming tadpoles by 
transplanting nuclei from blastula cells into enucleated Rana pipiens (frog) eggs.  
Thereafter, Gurdon et al. generated normal and fertile adult frogs by transferring 
tadpole intestinal epithelial cell nuclei into enucleated Xenopus laevis eggs 
(Gurdon et al., 1966; reviewed in Gurdon and Byrne 2003).  These results led to 
the conclusion that the process of cell differentiation does not involve irreversible 
changes in genetic content but only epigenetic changes that dictate gene 
expression patterns.  As cells undergo progressive loss of developmental 
potential during cell-fate specification, their genomic content remains the same 
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(with lymphocytes being an exception) and the process of specification can be 
entirely reversed so that cells regain pluripotency. 
The next major advance in SCNT was in the cloning of mammalian 
species, including Dolly the Sheep (Wilmut et al., 1997; Wakayama et al., 1998; 
Kato et al., 1998; Baguisi et al., 1999).  A normal adult sheep was produced by 
transplanting mammary gland cells of an adult sheep into enucleated sheep eggs 
(Wilmut et al., 1997).  This critical experiment demonstrated that cell 
differentiation was also reversible in mammalian cells.  More recently, SCNT has 
been confirmed in non-human primates.  Rhesus macaque embryonic stem (ES) 
cells were generated from adult nuclei by reprogramming via SCNT; nuclei from 
adult skin fibroblast cells were transplanted into enucleated oocytes and cells 
from the inner cell mass of the resulting blastocyst were cultured to generate ES 
cells (Byrne et al., 2007).  These ES cells contained the same genetic 
information as donor cells, with the exception of mitochondrial DNA originating 
from oocytes.  These ES cells exhibited typical ES cell morphology, expressed 
stem cell markers, OCT4, SSEA-4, TRA1-60 and TRA1-81, and differentiated 
into cells of the three embryonic germ layers (Byrne et al., 2007). 
Despite progress in non-human primates, the reprogramming of adult 
human somatic cells has been wrought with difficulty and successful SCNT in the 
human system remains elusive.  However,  a few breakthroughs in the 
reprogramming of human somatic cells have occurred in recent years.  First, 
reprogramming of human cells has been achieved by fusion of human somatic 
cells with human ES cells to form tetraploid hybrids.  This ES cell fusion process 
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reprograms the somatic cell nucleus to a pluripotent state (Cowan et al., 2005; 
Yu et al., 2006).  Second, while the feasibility of human SCNT remains to be 
seen, Noggle et al. have demonstrated that human oocytes have the capacity to 
reprogram human somatic cells to pluripotency (Noggle et al., 2011).  The 
transplantation of human somatic cell nuclei into enucleated human oocytes 
resulted in developmental arrest at late cleavage stages.  However, when a 
somatic cell genome was transplanted into an oocyte with its genome intact, the 
oocytes developed to the blastocyst stage.  Human stem cells derived from these 
blastocysts were triploid, containing the haploid oocyte genome and the diploid 
donor somatic cell genome that has been reprogrammed to a pluripotent state 
(Noggle et al., 2011). 
The results from these reprogramming experiments in mammalian species 
demonstrate that, as in earlier amphibian experiments, the genomic content of 
pluripotent cells remains the same as they undergo cell-fate specification.  The 
molecular changes that occur during cellular differentiation are epigenetic 
modifications and given the right context, these epigenetic modifications in 
somatic cells can be reversed so that the cells return to a pluripotent state.   
Despite advances in SCNT, the specific nature of the trans-acting factors 
present in oocytes and ES cells that mediate reprogramming remain unknown.  
However, a novel nuclear reprogramming strategy has emerged in recent years 
that offers insight into this question.  Pioneered by Dr. Shinya Yamanaka, this 
technology, termed induced pluripotent stem (iPS) cell technology, utilizes 
ectopic expression of defined transcription factors, Oct4, Sox2, Klf4 and c-Myc, 
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to reprogram somatic cells to a pluripotent state.  Somatic cells reprogrammed in 
this way are termed iPS cells. 
 
Nuclear reprogramming by defined factors - induced pluripotent stem (iPS) 
cell technology 
Reprogramming strategies for mouse and human iPS cells 
 Induced pluripotent stem (iPS) cell technology is a nuclear reprogramming 
strategy that allows for reprogramming of somatic cells to a pluripotent state 
using defined transcription factors.  The resulting iPS cells are similar to ES cells 
derived from blastocysts in both form and function. 
 The reprogramming of somatic cells through cellular fusion with ES cells 
had indicated that factors exist within ES cells that can induce pluripotency.  
Takahashi and Yamanaka hypothesized that factors that induce pluripotency 
may also play a role in maintaining pluripotency, and furthermore, that ectopic 
expression of these factors may be able to reprogram somatic cells to 
pluripotency.  This reasoning led to their finding in 2006 that retroviral 
transduction of four transcription factors, Oct4, Sox2, Klf4, c-Myc, and selection 
for the expression of Fbx15, a transcription target of pluripotency factors Oct4 
and Sox2, enabled the reprogramming of mouse embryonic and adult fibroblast 
cells to a pluripotent state (Takahashi and Yamanaka, 2006).  These four 
transcription factors all play a role in pluripotency. The reprogrammed iPS cells 
possessed many features of embryonic stem (ES) cells including  morphology, 
proliferation and the ability to differentiate into cells from all three germ layers.  
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They also expressed characteristic ES cell markers, including alkaline 
phosphatase, Nanog and mouse ES cell-specific surface marker, SSEA-1.  
However, these Fbx15-selected iPS cells differed significantly from mouse ES 
cells in their gene expression profiles and DNA methylation patterns.  Moreover, 
chimeras from Fbx15-selected iPS cells were embryonic lethals.  Subsequently, 
isolation of germline-competent iPS cells was achieved via selection for Nanog or 
Oct4 (Okita et al., 2007; Maherali et al., 2007; Wernig et al., 2007).  The 
discrepancy between these two selection systems stems from Fbx15 being 
dispensable for pluripotency whereas Nanog and Oct4 being critical for the 
maintenance of pluripotency (Tokuzawa et al., 2003). The capacity for germline-
transmission is critical because it is the most definitive criteria for pluripotency.   
 Nanog-selected and Oct4-selected mouse iPS cells were epigenetically 
and functionally virtually identical to mouse ES cells.  Their the global gene 
expression profile, DNA methylation pattern and histone modification pattern 
were similar to that of mouse ES cells (Okita et al., 2007; Maherali et al., 2007; 
Wernig et al., 2007).  These iPS showed typical ES cell gene expression, 
including Nanog, Eras, Esg1, Cripto and Rex1.  Bisulphite genomic sequencing 
analyses showed that promoter regions of Nanog and Oct4 were vastly 
unmethylated, like that of ES cells.  In female Nanog-selected iPS cells, silenced 
X chromosomes were reactivated and furthermore, underwent random X-
inactivation when subjected to differentiation (Maherali et al., 2007).  Beyond the 
molecular level, mouse iPS cells recapitulated two functional criteria that define 
stemness: the ability for self-renewal and the capacity to differentiate into cells of 
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all three embryonic germ layers.  Mouse iPS cells have been shown to 
differentiate into cells of the ectoderm, endoderm and mesoderm in both in vitro 
differentiation and in vivo teratoma formation when injected into immunodeficient 
mice (Okita et al., 2007; Maherali et al., 2007; Wernig et al., 2007).  Adult 
chimeras generated from mouse iPS cells show germline transmission (Okita et 
al., 2007; Boland et al., 2009) and can give rise to viable mice through tetraploid 
complementation (Zhao et al., 2009; Kang et al., 2009). 
 Following the generation of mouse iPS cells, human orthologs of Oct4, 
Sox2, Klf4, and c-Myc have been shown to successfully reprogram human 
somatic cells to iPS cells (Takahashi et al., 2007).  Additionally, an alternative set 
of transcription factors, Oct4, Sox2, Nanog and Lin28 have also been shown to 
induce pluripotency in human somatic cells (Yu et al., 2007).  Subsequently, 
human iPS cells have been successfully generated from embryonic, neonatal 
and adult fibroblasts using both sets of transcription factors and combinations of 
the two (Takahashi et al., 2007; Yu et al., 2007; Park et al., 2008b; Lowry et al., 
2008).  Like their mouse iPS cell counterparts, human iPS cells are similar to 
human ES cells, meeting epigenetic and functional criteria for pluripotency.  
Human iPS cells are similar to human ES cells in morphology, cell-growth rates, 
global gene expression profile and DNA methylation status.  They express ES 
cell markers, including alkaline phosphatase, Nanog, and human ES cell-specific 
surface markers SSEA-3, SSEA-4, Tra-1-60 and Tra-1-80. Bisulphite genomic 
sequencing analyses showed that promoter regions of Nanog, Oct4, and Rex1 
were vastly unmethylated, like that of human ES cells.  Additionally, human iPS 
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cells can differentiate into cells of three germ layers in vitro and form teratomas 
when injected into immunodeficient mice (Takahashi et al., 2007; Yu et al., 2007; 
Park et al., 2008b; Lowry et al., 2008).  Beyond fibroblasts, various sources of 
somatic tissue have been reprogrammed to pluripotency, including B 
lymphocytes (Hanna et al., 2008), hepatocytes (Aoi et al., 2008), keratinocytes 
(Aasen et al., 2008), adipose tissue (Sun et al., 2009), and hematopoietic cells 
(Loh et al., 2009). 
 The maintenance of pluripotency in mouse and human iPS cells does not 
depend on continual viral transgene expression.  Studies using doxycycline-
inducible lentiviral expression vectors for delivery of reprogramming factors have 
demonstrated that viral transgene expression for about two weeks is sufficient for 
establishment of stable pluripotency (Wernig et al., 2008; Stadtfeld et al., 2008a).  
This period of viral transgene expression is thought to initiate a reprogramming 
process involving stochastic events that lead to induction of pluripotency.  The 
reprogramming process causes changes in the epigenetic state of somatic cells 
that becomes indistinguishable from ES cells derived from the inner cell mass of 
blastocysts.  Critically, Dnmt3a and Dnmt3b methyltransferases become 
activated and silence gene expression from the reprogramming viruses.  
Endogenous pluripotency genes become reactivated (Jaenisch and Young 2008; 
Brambrink et al., 2008).  It is remarkable that the same four factors for 
pluripotency in mice were also able to induce pluripotency in human cells, even 
without selection for a pluripotency marker.  This may indicate that a canonical 
gene network governing pluripotency exists in mammalian species.  
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Making iPS cells suitable for clinical applications: modifications to initial 
reprogramming strategies  
One of the greatest utility for nuclear reprogramming is in the generation of 
patient-specific cell replacement therapies.  The advent of iPS cell technology 
has made this goal more feasible than ever before.  However, concerns 
regarding the use of viral vectors and reactivation of potent oncogenes c-MYC 
and Klf4 need to addressed before this end can be achieved.  Indeed, much 
research has focused on eliminating these concerns and generating iPS cells 
that are suitable for clinical purposes.      
 Transduction of somatic cells with retroviruses and lentiviruses result in 
random integration of viruses into the host genome.  These integrations can 
result in potential oncogenesis due to insertional mutagenesis; proviruses 
integrated into the host genome can affect expression of nearby genes, leading 
to oncogenesis, as seen in preclinical and clinical gene therapy trials (Li et al., 
2002; Hacein-Bey-Albina et al., 2003; Howe et al., 2008).  Furthermore, while 
integrated proviruses are silenced during iPS cell generation, viral transgenes 
have the potential to be reactivated.  Indeed, reactivation of retroviral c-Myc has 
been found to cause tumors in mouse chimeras generated from iPS cells 
(Takahashi and Yamanaka 2006; Okita et al., 2008).  To address this concern, 
several groups have shown that reprogramming can be achieved in mouse and 
human cells without the use of c-MYC.  Chimeric mice generated with mouse iPS 
cells were tumor-free (Wernig et al., 2008; Nakagawa et al., 2008).  The 
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drawback of removing c-MYC from the pool of reprogramming factors is that 
reprogramming efficiency, typically ranging from 0.01% - 0.05%, becomes very 
low, up to one order of magnitude lower and the reprogramming kinetics is 
slower (time to iPS cell colony formation is increased). 
 Given the concerns of genomic integration of viral vectors, methods for 
reprogramming without viral integration have been developed.  Non-integrating 
adenoviruses that allow for transient expression of the reprogramming factors 
have been shown to reprogram murine and human somatic cells but with low 
efficiency (Stadtfeld et al., 2008b; Zhou and Freed, 2009).  Additionally, the 
Cre/LoxP recombination system has been utilized so that integrated viral 
transgenes can be excised after generation of stable iPS cell lines (Kaji et al., 
2009; Sommer et al., 2010).  However, the Cre/LoxP system is not optimal since 
residual vector sequences remain after removal of transgenes.  Clean excision of 
viral transgenes has been shown using the piggyBac transposon system in both 
mouse and human somatic cells.  After induction of pluripotency, randomly 
integrated reprogramming factors can be removed without leaving behind any 
sequences or changes to the genome (Woltjen et al., 2009).  Furthermore, 
polycistronic lentiviral vectors that contain the original four reprogramming 
factors, Oct4, Sox2, Klf4 and c-Myc, in a single lentiviral construct have been 
shown to successfully reprogram human fibroblasts to pluripotency with only 
single vector integrations (Sommer et al., 2009; Carey et al., 2009).  The 
combination of the piggyBac transposon system with polycistronic lentiviral 
vectors may be an optimal system to achieve transgene-free iPS cells.    
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Completely viral-free methods have also been successfully employed to 
generate iPS cells, including plasmid transfection (Okita et al., 2008) and whole 
protein delivery of reprogramming factors (Zhou et al., 2009, Kim et al., 2009).  
The plasmid approach involves repeated transfection of two expression 
plasmids, one encoding Oct4, Sox2 and Klf4 cDNAs and the other encoding c-
Myc cDNA.  In the protein approach, reprogramming has been achieved by either 
using reprogramming factors along with pharmacological induction of cell 
permeability or reprogramming factors tagged to polyarginine for cell permeation 
(Zhou et al., 2009).  Viral-free iPS reprogramming strategies result in even lower 
reprogramming efficiencies than the non-viral integration strategies.  
 Concerns regarding low reprogramming efficiency have been addressed 
with the use of small molecules involved in chromatin modification, which can 
increase reprogramming efficiency.   The DNA methyltransferase inhibitor 5’-
azacytidine has been shown to increase reprogramming efficiency about tenfold.  
Histone deacetylase inhibitors including, suberoylanilide hydroxamic acid, 
trichostatin A, and valproic acid also increase reprogramming efficiency, with 
valproic acid being most efficacious, increasing reprogramming efficiency more 
than 100-fold (Huangfu et al., 2008a).  Valproic acid has also been shown to 
substitute for c-MYC and Klf4 factors, allowing for reprogramming of human 
fibroblasts to pluripotency with just Oct4 and Sox2 (Huangfu et al., 2008b; Shi et 
al., 2008).   
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 Another means to increase reprogramming efficiency is by inhibiting the 
tumor suppressor gene p53, which has been shown to inhibit the reprogramming 
process.  Transient siRNA-mediated knockdown of p53 or overexpression of 
MDM-2 to increase p53 degradation results in the increase of reprogramming 
efficiency by one to two orders of magnitude (Banito et al., 2009; Hong et al., 
2009; Li et al., 2009; Marion et al., 2009; Kawamura et al., 2009). These 
advances in reprogramming strategy are paving the way towards clinical 
application of iPS cells. 
 
The generation of patient-specific iPS cells 
 While much excitement surrounds the use of iPS cells for patient-specific 
cell replacement therapies, another critical utility of iPS cells is the generation of 
disease-specific cell-based models for the study of human diseases.  These 
human cell-based models are crucial for diseases that cannot be fully 
recapitulated through in vitro or animal models.  A proof-of-concept experiment 
has shown that human iPS cell lines can be generated from fibroblasts obtained 
from patients with a variety of diseases ranging from genetic diseases with 
Mendelian inheritance to complex multi-factorial diseases, including adenosine 
deaminase deficiency-related severe combined immunodeficiency (ADA-SCID), 
Gaucher’s disease (GD) type III, Duchenne’s muscular dystrophy (DMD), 
Huntington’s disease (HD), Parkinson’s disease (PD), juvenile-onset, type 1 
diabetes milletus (JDM), and Down’s syndrome (DS) (Park et al., 2008a).  
Patient-specific iPS cell lines display characteristic ES cell morphology, express 
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markers of pluripotency, and form cells of the three primary germ layers in vitro 
differentiation and in vivo formation of teratomas in immunodeficient mice.   
 Furthermore, another proof-of-concept experiment has shown that iPS 
cells can be derived from fibroblasts cells of elderly patients.  Fibroblasts cells 
isolated from patients with amyotrophic lateral sclerosis in their eighth decade of 
life was successfully reprogrammed to pluripotency (Dimos et al., 2008).  This 
experiment confirmed that iPS cells can be generated from elderly patients with 
progressive neurodegenerative disease, a group that is most likely to benefit 
from cell replacement therapies.  The ability to generate patient-specific iPS cells 
offers an unparalleled opportunity to recapitulate human disease pathology in 
vitro.  These human cell-based disease-specific models may provide tremendous 
aid in the elucidation of disease pathophysiologies and facilitate drug-screens for 
therapeutic advances (see Chapter 1, Section C).   
 
Direct lineage reprogramming by defined factors - induced neuronal (iN) 
cell technology 
While nuclear reprogramming results in the resetting of somatic cells to a 
pluripotent state, somatic cells can also be induced to express traits of other cell 
types via ectopic expression of lineage-specific transcription factors, a process 
classically referred to as trans-differentiation.  Various experiments have 
demonstrated this conversion between closely related cell lineages arising from 
the same germ layer.  Ectopic expression of MyoD, a muscle cell-specific 
transcription factor, converts fibroblasts to myoblast-like cells (Davis et al., 1987; 
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Weintraub et al., 1989).  Lineage-committed B and T cells can be reprogrammed 
to macrophage-like cells via ectopic expression of myeloid transcription factor 
C/EBPalpha (Xie et al., 2004; Laiosa et al., 2006).  Fibroblasts can also be 
converted to macrophage-like cells via ectopic expression of PU.1 and 
C/EBPalpha/beta (Feng et al., 2008).  Additionally, lymphoid progenitor cells can 
be converted to myeloid cells by ectopic expression of IL2 and GM-CSF 
receptors (Kondo et al., 2000).  Furthermore, pancreatic exocrine cells can be 
reprogrammed in vivo to endocrine insulin-producing beta cells via forced 
expression of Ngn3, Pdx1 and MafA, three transcription factors required for beta-
cell differentiation, (Zhou et al., 2008).  
More remarkably, a recent advance in reprogramming technology has 
demonstrated that this direct lineage conversion can occur between cells from 
vastly different cell lineages, arising from different germ layers.  In 2010, 
Vierbuchen et al. demonstrated that lentiviral expression of a set of transcription 
factors involved in neuronal development, Brn2, Ascl1, and Myt1l, Olig2 and 
Zic1, directly reprogrammed mouse fibroblasts to induced neuronal (iN) cells.  
Further investigation revealed that expression of only Brn2, Ascl1, and Myt1l, 
were sufficient for this conversion.  Induced neuronal cells showed typical 
neuronal morphology, expressed mature neuronal markers, including Tuj1, 
NeuN, MAP2, and synapsin and exhibited functional neuronal properties, 
including the ability to generate action potentials and functional synapses.  The 
majority of iN cells were glutamatergic, expressing marker vGLUT1 and a 
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minority expressed markers of gabaergic neurons, GABA (Vierbuchen et al., 
2010).   
Unlike reprogramming to pluripotency, where the same set of transcription 
factors is effective for reprogramming both mouse and human somatic cells, 
direct reprogramming of human fibroblasts to neurons was shown to require an 
additional transcriptional factor, NeuroD1 (this phenomenon speaks to the fact 
that different regulatory networks govern human and rodent neuronal 
development).  Forced expression of Brn2, Ascl1, Myt1l, and NeuroD1 converted 
primary human fetal and postnatal fibroblasts into functional iN cells (Pang et al., 
2011). The efficiency of conversion ranged from 2%-4%.  These human iN cells 
displayed typical neuronal morphology and expressed neuronal markers, Tuj1, 
NeuN, PSA-NCAM, and MAP2.  Single-cell gene-expression profiling revealed 
co-expression of pan-neuronal and synaptic markers, including β-III-tubulin, 
DCX, MAP2, NCAM, and synapsin.  The majority of neurons seemed to be 
glutamatergic, expressing vGLUT1 and vGLUT2 mRNAs.  In electrophysiological 
analyses, hiN cells generated action potentials and demonstrated voltage-
dependent Na+ channel activity.  Human iN cells also formed functional 
synapses.  These cells showed GABA and glutamate receptor activity.  
Additionally, after co-culture with primary mouse cortical neurons, whole-cell 
recordings of human iN cells showed spontaneous postsynaptic currents, 
including both inhibitory postsynaptic currents (IPSCs) and excitatory 
postsynaptic currents (EPSCs).    
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After initial reports of direct reprogramming to neuronal cells, additional 
studies have shown that fibroblasts can be directly reprogrammed to various 
other cell types including cardiomyocytes (Ieda et al., 2010), blood progenitors 
(Szabo et al., 2010) and hepatocytes (Huang et al., 2011; Sekiya and Suzuki, 
2011).  Additionally, hepatocytes have been directly converted to functional 
neurons (Marro et al., 2011).  These direct cell-fate conversions were mediated 
by ectopic expression of lineage-specific transcription factors.   
Like iPS cell technology, iN cell technology has the utility for modeling 
neurological diseases and in particular, for neurodegenerative diseases (see 
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Chapter 1. C. Cell-based modeling of neurodegenerative diseases using 
iPS vs. iN cell reprogramming technology 
 
Modeling neurodegenerative diseases using cellular reprogramming 
technologies 
Two cellular reprogramming technologies have emerged that demonstrate 
that cell fate can be converted by ectopic expression of defined transcription 
factors: induced pluripotent stem (iPS) cell technology and induced neuronal (iN) 
cell technology.  While both iPS cell technology and iN cell technologies can be 
utilized to generate human cellular models of neurodegenerative diseases, these 
molecular tools allows for the achievement of that end through direct and indirect 
means, respectively.  Disease modeling via iPS cell technology is a two-step 
process that requires first the generation of iPS cells from patient somatic cells 
(usually skin fibroblasts) and subsequent directed differentiation of patient-
specific iPS cells into specific neuron subtypes.  In contrast, iN cell technology 
enables generation of patient-specific neuronal cells in one direct reprogramming 
step.   
While much work is necessary to further develop these technologies, as a 
whole, patient-specific models have been able to recapitulate molecular and 
cellular pathologies of various neurodegenerative diseases.  These patient-
specific models can enable us to understand diseases in a human cellular 
context.  Furthermore, nuclear reprogramming technologies have made possible 
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the modeling of sporadic forms of neurodegenerative diseases, which when 
present, comprise the most prevalent forms.  
 
The utility of bioengineered human cellular models for studying 
neurodegenerative diseases 
There is an essential need for human cellular models of 
neurodegenerative disorders because current cellular and animal models are 
inadequate. In particular, cell reprogramming-based models can provide a 
powerful means for elucidating the molecular mechanisms for selective loss of 
specific neuron cell types, a defining feature of neurodegenerative disorders.  
Patient-specific disease models offer the unprecedented opportunity for 
examining disease pathophysiology within the human neuronal context, and 
furthermore, within the genetic backgrounds of patients.  Because primary 
human neurons are inaccessible, previous cellular models for neurodegenerative 
diseases have been based on available tissue, such as human cancer cell lines 
and patient fibroblast cell lines, but these models cannot recapitulate the unique 
neuronal environment in which disease pathology occurs.  In this regard, primary 
neuronal cultures from animal models have been used in studies but this 
approach also has its limitations since these models do not fully recapitulate 
clinical disease phenotypes and are therefore limited in their representation of 
disease pathophysiology.  Indeed, drugs found to be effective in mouse models 
have generally not been therapeutic in human clinical trials.  Furthermore, for 
many neurodegenerative diseases, only about 5%-10% of cases are familial, 
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attributable to specific genetic mutations, while the majority of cases are 
sporadic, involving a complex interplay between genetic factors and 
environmental insults.  Cell reprogramming technologies uniquely enable the 
modeling of sporadic forms of neurodegenerative diseases, as it is impossible to 
generate sporadic animal models.  
Patient-specific disease models are also particularly useful in the context 
of neurodegenerative diseases for examining the ontogenesis of neuronal cell 
death.  Most neurodegenerative disorders are late onset while iPS cell-derived 
neurons or iN cells are newly derived neurons and it would be surprising to see 
neuronal loss phenotypes in cellular models of late onset disorders.  However, 
these young neurons may be representative of pre-disease stage neurons.  
Modeling of this pre-disease state permits development of assays for identifying 
exogenous factors that instigate or promote cellular phenotypes and neuronal 
cell death.  Indeed, for all neurodegenerative diseases with mid to late onset that 
have been modeled from cellular reprogramming technologies thus far, including 
amyotrophic lateral sclerosis (ALS) (Dimos et al., 2008), Alzheimer’s disease 
(AD) (Yagi et al., 2011), Parkinson’s disease (PD) (Hargus et al., 2010; Nguyen 
et al., 2011; Seibler et al., 2011), and Huntington’s disease (HD) (Zhang et al., 
2010), there has been no report of neuronal death phenotypes.  Conversely, cell 
reprogramming-based models that do exhibit neuronal death phenotypes are 
useful in screening for drugs that can slow progression of neuronal loss.  For 
example, in the case of spinal muscular atrophy (SMA) type 1, where the age of 
onset is before six months, a SMA type 1 patient-specific cell model potentially 
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recapitulates the phenotype of motor neuron cell death (Ebert et al., 2009).  If so, 
this model would be particularly useful in screening for drugs that hinder neuronal 
cell death in SMA type 1.   
Various groups have modeled neurodegenerative diseases using both iPS 
and iN cell reprogramming strategies.  Patient-specific iPS cell-derived neurons 
have been generated from somatic cells of sporadic and genetic forms of 
neurodegenerative diseases.  In the case of genetic disease, iPS cells and 
subsequent iPS cell-derived neurons have been shown to maintain the genetic 
mutation found in the starting somatic cells.  On the iN cell-based modeling front, 
cortical glutamatergic neurons, motor neurons, and dopaminergic neurons have 
been directly reprogrammed from fibroblasts, allowing for the potential modeling 
of diseases such as AD, ALS, SMA and PD. 
 
Advantages and limitations of iPS and iN cell technologies for disease 
modeling 
IPS and iN cell technology each has its own advantages and limitations for 
disease modeling.  Indeed, these two approaches to cellular reprogramming are 
being explored vigorously for cell-based modeling of neurodegenerative 
diseases.  What are the pros and cons of these two novel molecular tools and 
which should be utilized to create patient-specific disease models?   
With regards to ease of reprogramming and efficiency, iN cell technology 
is at an advantage.  Relative to iN cell reprogramming, iPS cell reprogramming is 
labor intensive, time consuming, and inefficient.  The neuronal yield from iN cell 
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reprogramming ranges from 2%-9% (Vierbuchen et al., 2010; Pang et al., 2011) 
whereas the efficiency in iPS cell reprogramming is typically about 0.01% -0.05% 
(Okita et al., 2007; Takahashi et al., 2007; Yu et al., 2007).  Furthermore, there is 
variability in differentiation efficiency both across iPS cell lines and within iPS cell 
lines, from one differentiation experiment to the next.  Moreover, the iPS cell 
approach is tremendously labor intensive and time consuming.  The derivation of 
one iPS line, from the time of fibroblast infection to establishing a stable line, 
takes at least one to two months and subsequent differentiation of iPS cells into a 
specific desired neuron type takes at least four to six weeks.  In contrast, iN cell 
reprogramming generates neurons in about three weeks and cultures are 
relatively easy to maintain. 
However, with respect to generating specific neuronal cell types, iPS cell 
technology may be at an advantage.  Thus far, only a handful of neuronal 
subtypes have been generated via iN cell technology, including cortical 
glutamatergic neurons, motor neurons, and dopaminergic neurons (Pang et al., 
2011; Son et al., 2011; Kim et al., 2011). Furthermore, these human induced 
neuronal cells appear to be less mature in their functional properties (e.g., the 
ability to form functional synapses) relative to iPS-cell derived neurons or primary 
neurons (Yang et al., 2011).  In addition, if other neuronal subtypes are desired 
(for example medium spiny neurons for the modeling of Huntington’s disease), 
the transcription factors would have to be newly determined.  Moreover, it is 
uncertain whether all neuronal cell types (relevant for neurodegenerative disease 
modeling) can be generated by direct reprogramming (although current progress 
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in the field seems to suggest this is possible).  In consequence, iPS cells may be 
more useful for cell-based disease modeling; in theory, they have the potential to 
generate all types of neurons and indeed various neuronal differentiation 
protocols exists and neuronal cell types with mature functional properties have 
been differentiated from ES cells and iPS cells. 
Lastly, the utility of iPS vs. iN cell reprogramming technologies for 
modeling neurodegenerative diseases ultimately depends on feasibility for 
meaningful experiments.  Direct cell reprogramming technology is advantageous 
for large-scale studies as it is relatively easy to generate iN cells from a large 
sample of patients.  In contrast, it would be very labor, time, and cost intensive to 
generate and differentiate a large panel of patient-specific iPS cell lines. 
However, iPS cell technology would be useful for studying intermediate cell types 
such as neuronal precursors, which would be impossible using iN cell technology 
since direct reprogramming precludes intermediate developmental cell stages.   
 
iPS-cell based models of neurodegenerative diseases  
Amyotrophic lateral sclerosis (ALS) 
 The modeling of ALS using iPS cell technology was the first proof-of-
concept experiment that demonstrated that iPS cells can be derived from 
fibroblasts cells of elderly patients.  Fibroblast cells isolated from patients with 
ALS in their eighth decade of life was successfully reprogrammed to pluripotency 
(Dimos et al., 2008).  
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ALS is characterized by a progressive loss of motor neurons in the spinal 
cord and motor cortex.  Disease progression results in weakening and wasting of 
muscles, leading to paralysis and death, typically within 1-5 years of initial 
diagnosis (Pasinelli et al., 2006).  Using retroviral transduction of Oct4, Sox2, 
Klf4, and c-Myc (Takahashi et al., 2007), iPS cells were generated from the skin 
cells of a 82-year-old patient harboring a mutation in the SOD1 gene.  These 
ALS patient-specific iPS cells were subsequently differentiated into two cell types 
thought to be involved in the pathophysiology of ALS: motor neurons and glia.  
The patient-specific motor neurons express motor neuron markers, HB9 and 
Islet1/2.  Glial cells expressed glial markers, GFAP and S100.  Further 
characterization of these cells is necessary for examining molecular and cellular 
phenotypes (Dimos et al., 2008). 
 
Spinal muscular atrophy (SMA)  
 The modeling of SMA using iPS cell technology was the first proof-of-
concept experiment that demonstrated the utility of iPS cell-based models in drug 
screens.  iPS cells derived from SMA patients were able to differentiate into 
motor neurons that responded to compounds known to increase SMN protein 
levels, a key pathological feature in SMA (Ebert et al., 2009).   
SMA is a neurodegenerative disorder caused by autosomal recessive 
mutation in the survival motor neuron 1 gene (SMN1), resulting in the selective 
loss of lower motor neurons.  At the molecular level, SMA is characterized by 
reduced SMN gene transcripts and SMN protein expression (Lefebvre et al., 
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1995; Coovert et al., 1997). SMA patient-specific iPS (SMA-iPS) cells have been 
generated from SMA type 1 patient fibroblasts via lentiviral transduction of Oct4, 
Sox2, Nanog and Lin28 (Yu et al., 2007).  SMA-iPS cells show reduced levels of 
full-length SMN gene transcripts.  Extended culturing of SMA-iPS cell motor 
neuron differentiation cultures resulted in significantly fewer motor neurons with 
reduced size, relative to control iPS cell differentiation cultures.  As such, the 
disease phenotype may selectively impede the generation of motor neurons 
and/or promote the degeneration of motor neurons.  SMA-iPS cell-derived motor 
neurons responded to SMN-inducing compounds, valproic acid and tobramycin, 
resulting in a significant increase in SMN protein levels.  
 
Alzheimer’s disease (AD) 
Like iPS cell-based model for SMA type 1, the iPS cell-based model for 
AD provide an important proof-of-principal for using iPS cell-based models in 
drug screens (Yagi et al., 2011).  iPS cells derived from AD patients were able to 
differentiate into neurons that responded to compounds that modulated Aβ 
levels, the putative mediators of AD pathophysiology.   
AD is the most common neurodegenerative disorder and most common 
cause of dementia in the elderly.  Neuronal degeneration in AD occurs in the 
forebrain and hippocampal regions.  The hallmark pathological features of AD 
include extracellular amyloid beta (Aβ) plaques and intracellular neurofibrillary 
tangles (Alzheimer et al., 1995). Retroviral transduction of Oct4, Sox2, Klf4, 
Lin28 and Nanog has been used to generate iPS cells from familial AD (FAD) 
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patient fibroblasts containing mutations in the PSEN1 and PSEN2 genes.  
Neurons derived from FAD patient-specific iPS  (FAD-iPS) cells show increased 
Aβ42:Aβ40 ratio, a molecular feature of FAD.  FAD-iPS cell-derived neurons also 
responded to γ-secretase inhibitors and modulators, drugs known to affect Aβ 
levels; neurons show dose-dependent reduction in Aβ42 and Aβ40 levels when 
exposed to compound E, a strong γ-secretase inhibitor and reduction in 
Aβ42:Aβ40 ratio when exposed to compound W, a selective Aβ42 lowering agent 
(Yagi et al., 2011). 
 
Parkinson’s disease (PD)  
A few patient-specific iPS cell-based models of PD have been generated 
that demonstrate both the utility of iPS cell technology for in vitro disease 
modeling and in regenerative medicine. PD, the second most prevalent 
neurodegenerative disorder, is characterized by progressive loss of midbrain 
dopaminergic neurons in the substantia nigra while sparing dopaminergic 
neurons in the ventral tegmentum.  Clinical features include both motor and 
cognitive symptoms. 
iPS-cell based models of genetic forms of PD have been generated from 
patients with mutations in LRRK2 or PINK1 (Nguyen el at., 2011; Seibler et al., 
2011).  The iPS cell-based LRRK2 PD model was generated using fibroblasts 
from a PD patient who carries the LRRK2 G2019S mutation.  Retroviral 
transduction of Oct4, Sox2, and Klf4 reprogrammed patient fibroblasts to iPS 
cells.  Dopaminergic neurons derived from LRRK2 PD patient-derived iPS (PD-
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iPS) cells expressed dopaminergic marker TH, and other midbrain neuronal 
markers, including NURR1, PITX3, and FOX2A.  LRRK2 PD-iPS cell-derived DA 
neurons exhibited key features of PD pathology, including increased levels of α-
synuclein protein and oxidative stress genes (Nguyen el at., 2011).  The iPS-cell 
based PINK1 PD model was generated using fibroblasts from PD patients with 
mutations in the PINK1 gene.  Fibroblasts were reprogrammed to pluripotency 
using retroviral transduction of Oct4, Sox2, Klf4 and c-Myc along with valproic 
acid treatment, a histone deacetylase inhibitor that has been found to increase 
the efficiency of pluripotency induction.  Dopaminergic neurons derived from 
PINK1 PD-iPS cells displayed a previously described phenotype, in which Parkin 
(another protein implicated in the pathogenesis of PD) recruitment to the 
mitochondria is impaired.  This phenotype was rescued with overexpression of 
wild type PINK1 (Seibler et al., 2011).    
An iPS-cell based model of sporadic PD was derived from sporadic PD 
patient fibroblasts using doxycycline (DOX)-inducible lentiviral vectors that 
encode either Oct4, Sox2, Klf4, and c-Myc (4F) or 4F minus c-Myc (3F).  PD-iPS 
cells derived from 3F and 4F were both able to differentiate into dopaminergic 
neurons, expressing dopaminergic neuron marker TH.  Transgene free PD-iPS 
cells were further generated using DOX-inducible vectors that were excisable 
with cre-recombinase.  These cells also gave rise to dopaminergic neurons when 
subjected to directed differentiation (Soldner et al., 2009).  When transplanted 
into the striatum of adult rodent brain, transgene-free PD-iPS cell-derived 
dopaminergic (DA) neurons survived for up to 16 weeks.  Furthermore, 
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transplantation of PD-iPS cell-derived DA neurons into the striatum 6-OHDA-
lesioned rats, a behavioral model of PD, resulted in partial functional recovery; 
lesioned rats that received cell transplantations showed reduction in 
amphetamine- and apomorphine-induced rotations (Hargus et al., 2010).  
 
Huntington’s disease (HD)  
HD is an autosomal dominant neurodegenerative disease caused by 
expanded and unstable CAG repeats in the huntingtin gene (Duyao et al., 1993; 
The Huntington's Disease Collaborative Research Group, 1993).  HD is 
characterized by degeneration of striatal medium spiny neurons (MSNs) and to a 
lesser extent, cortical neurons.  Clinical features include progressive worsening 
chorea and cognitive decline leading to dementia. Retroviral transduction of 
Oct4, Sox2, Klf4 and c-Myc was used to reprogram fibroblasts from a HD patient 
with 72 CAG repeats in the huntingtin gene (Park et. al., 2008a).  These iPS cells 
derived from HD patients (HD-iPS cells) were subsequently differentiated into 
neural stem cells (NSCs) and mature medium spiny neurons (MSNs) that 
expressed markers, calbindin and DARPP-32 (Zhang et al., 2010).  The 
phenotype for HD-iPS cell-derived MSNs was not examined due to a low yield.  
However, in response to serum withdrawal, HD-iPS cell-derived NSCs showed 
elevation of caspase-3/7 activity, a known pathological feature of HD.  Although 
focused on HD patient-specific NSCs and not MSNs, this study nevertheless 
shows promise for iPS-cell based modeling of HD (Zhang et al., 2010).  
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iN cell-based models of neurodegenerative diseases  
 
Parkinson’s disease 
A number of studies have used different combinations of midbrain 
dopaminergic neuron-specific transcription factors to generate induced 
dopaminergic neuronal (iDA) cells, to varying degrees of success.  One study 
used a combination Lmx1a and Fox2a along with Brn2, Ascl1, and Myt1l 
(Vierbuchen et al., 2010) to reprogram fibroblasts (Pfisterer et al., 2011).  The 
resulting neurons expressed dopaminergic neuron markers TH, AADC and Nurr1 
but these cells were unable to release dopamine, the critical functional activity of 
dopaminergic neurons (Pfisterer et al., 2011).  Another group, using transcription 
factors Asc1, Nurr1 and Lmx1, were able to reprogram PD patient fibroblasts to 
neurons that expressed a panel of dopaminergic neuron markers, including TH, 
VMAT2, DAT, ALDH1A1 and calbindin.  These neurons were capable of 
dopamine release, displaying the critical functional activity of dopaminergic 
neurons (Caiazzo et al., 2011).  Lastly, a third group, using a combination of 
transcription factors Ascl1, PitX3, Nurr1, Lmx1a, Fox2a and En1, were able to 
generate eGFP positive cells from PitX3:eGFP fibroblasts.  These cells 
expressed dopaminergic neuron markers TH, DAT, AADC and VMAT2 and were 
capable of dopamine release.  Transplantation of iDA neurons into the 6-OHDA 
PD model resulted in reduction of amphetamine-induced rotation.  This study 
illustrates the potential for iDA neurons for disease modeling (Kim et al., 2011).  
While these studies are promising as initial attempts for modeling PD, it is 
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important to note that iDA cells generated thus far have not displayed midbrain 
phenotype.  In future studies, it would be imperative to generate midbrain iDA 
(and from somatic cells of PD patients) in order to properly model PD using iN 
technology.   
 
Amyotrophic lateral sclerosis (ALS) 
Mouse fibroblasts have been reprogrammed to induced motor neurons 
(iMN) by retroviral transduction of Lhx3, HB9, Isl1, and Ngn2 along with Brn2, 
Ascl1, and Myt1l.  Induced motor neurons expressed HB9 and displayed 
functional neuronal properties, including the ability to form functional synaptic 
connections with myotubes.  When these iMN cells were co-cultured with glia 
that carried the SOD1 G93A mutation, a mutation found in familial form of ALS, 
iMN cell loss was detected.  While it remains to be seen whether iMN cells can 
be generated from ALS patient fibroblasts for modeling human disease, this 
study nevertheless shows the utility of iMN for elucidating molecular mechanisms 
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Chapter 2: Reprogramming AD patient fibroblasts to induced pluripotent 
stem (iPS) cells 
 
Introduction 
Recent advances in cellular reprogramming technologies have fueled 
excitement for the generation of human cell-based models of neurological 
diseases and patient-specific cellular replacement strategies in regenerative 
medicine.  Our aim was to utilize induced pluripotent stem (iPS) cell technology 
to generate a patient-specific iPS cell-based model of Alzheimer’s disease (AD).  
Our general strategy was to reprogram AD patient fibroblasts to pluripotency and 
subsequently differentiate these AD patient-specific iPS (AD-iPS) cells into 
cortical glutamatergic neurons.  For the purpose of content organization, the 
generation of AD-iPS cells and their subsequent differentiation into neurons are 
discussed in separate chapters but it would be useful to keep this greater context 
in mind when reading this chapter.    
Reprogramming experiments were conducted using familial AD (FAD) and 
sporadic AD (SAD) patient fibroblasts obtained from Coriell Cell Repository.  We 
conducted two rounds of experiments to generate AD patient-specific iPS (AD-
iPS) cell lines.  In the initial round of experiments, the reprogramming efficiency 
was low and the resulting iPS cell lines expressed few pluripotency markers.  In 
the second round of experiments, after modifying our protocol to increase 
efficiency of reprogramming and improve our method of screening for iPS cell 
colonies, we were able to isolate and expand a group of partially reprogrammed 
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FAD-, SAD- and control-iPS cell lines.  These partially reprogrammed iPS cells 
lines expressed some pluripotent markers, including Oct4, Nanog and Tert.  
 
Results 
Generation of AD patient-specific iPS cell lines: initial round of experiments  
In an initial attempt to generate AD patient-specific iPS (AD-iPS) cell lines, 
we used the viPS vector kit from Open Biosystems for lentiviral infection of FAD 
fibroblasts.  This vector kit consisted of six separate lentiviral expression vectors 
containing the cDNAs of human Oct4, Sox2, Klf4, c-Myc, Nanog and Lin28 genes 
under control of the constitutive human elongation factor-1 alpha (EF1α) 
promoter.  Previous studies had shown that human somatic cells can be 
reprogrammed to pluripotent stem cells via ectopic expression of a combination 
of either (1) Oct4, Sox2, Klf4, and c-Myc (Takahashi et al., 2007) or (2) Oct4, 
Sox2, Nanog and Lin28  (Yu et al., 2007).  We chose to use the original 
Yamanaka factors, Oct4, Sox2, Klf4, and c-Myc for reprogramming. 
Four individual viruses were generated and combined to make a stock 
virus for infecting FAD and control fibroblasts.  At 2-3 weeks after lentiviral 
transduction, cell colonies appeared.  The reprogramming efficiency was low, at 
about 0.01%.  Efficiency was determined by the formula, ((# colonies formed)/ 
(number of fibroblasts infected)) x (100). We manually picked and clonally 
expanded cell colonies.   After the fourth passage, colonies were maintained by 
enzymatic passaging using TrypLE (Invitrogen).  
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Characterization of pluripotency in first set of iPS cell lines 
We selected two AD-iPS cell lines, B2-iPS and C8-iPS, and one control 
iPS cell line, Z1-iPS, for characterization.  B2-iPS was generated from Coriell 
fibroblast line AG09908, which carries the PSEN2N141I mutation; C8-iPS was 
generated from Coriell fibroblast line AG06840, which carries the PSEN1246E 
mutation.  iPS cells were positive for pluripotent stem cell markers alkaline 
phosphatase (AP) and Oct4. However, Nanog levels were low, and surface 
markers SSEA-4, Tra-1-60 and Tra-1-81 could not be detected.  The morphology 
of these iPS cell colonies differed from that of human ES cell colonies, typically 
large, flat, and round colonies with well-defined borders.  In contrast, our iPS cell 
colonies were small and irregularly shaped, with ill-defined boundaries (Figure 1). 
Furthermore, upon cortical neuron differentiation, iPS cell lines were unable to 
generate cortical neurons (see Chapter 3).  
 
Generation of AD patient-specific iPS cell lines: second round of 
experiments  
Because the first set of iPS cell lines did not possess traits of pluripotency 
at both the molecular level and functional level, we performed a second round of 
reprogramming experiments to generate iPS cell lines.  In this second set of 
experiments, we modified our protocol to increase the likelihood of obtaining true 
iPS cells.    
One of the parameters we sought to improve was the efficiency of 
reprogramming, the rationale being that with more colonies available for 
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screening, there would be a greater chance to obtain genuine iPS colonies.  To 
increase the efficiency of reprogramming, we used a polycistronic lentiviral 
expression vector encoding the cDNAs of human Oct4, Sox2, Klf4, and c-Myc 
under control of the constitutive human elongation factor-1 alpha (EF1α) 
promoter (Sommer et al., 2010) (Figure 2).  Previous studies had shown 
reprogramming efficiency using this polycistronic vector (estimated at 0.05%) to 
be 10-fold higher than that observed for reprogramming achieved via multiple 
individual viral vectors (approximately 0.01%-0.05%) (Sommer et al., 2009; 
Sommer et al., 2010).  
Another parameter we modified was the morphological criteria used when 
screening plates for cell colonies, since having good morphology is critical for 
identifying potential iPS cell colonies.  We increased our stringency in evaluating 
morphology when selecting colonies for isolation, only picking colonies with 
excellent morphology: these colonies were sufficiently large, flat and round, with 
well defined borders and contained small cells with a high nucleus-to-cytoplasm 
ratio. 
Additionally, in this second round of experiments,  we also altered the 
method of viral infection, using repeated innoculations of unconcentrated viral 
supernatant rather than one innoculation of concentrated virus (Figure 3). In 
discussions with colleagues also conducting iPS cell reprogramming 
experiments, infection of cells using unconcentrated virus seemed to produce 
more consistent reprogramming results.  Additionally, using viral supernatant was 
more labor-efficient than using concentrated virus.  
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A total of ten FAD-iPS lines, twenty-two SAD-iPS lines and sixteen 
control-iPS lines were initially picked and clonally expanded.  Of these iPS cell 
lines, a total of  eighteen lines survived initial manual expansion and gave rise to 
stable cell lines.  Five of these iPS cell lines were derived from FAD patient 
fibroblasts: three, 9908-1, 9908-5, and 9908-6, from the Coriell fibroblast line 
AG09908 (containing the PSEN2N141I mutation) and two, 6840-3 and 6840-4, 
from the Coriell fibroblast line AG06840 (containing the PSEN1246E mutation).  
Seven of these iPS lines were derived from SAD patient fibroblasts, Coriell lines 
AG04401, AG04402, AG06262, AG06263, AG06264.  Finally, six of these iPS 
lines were derived from control fibroblasts, Coriell lines AG10788, AG07573, 
AG07871, and AG11368 (Figure 4).  
The efficiency of reprogramming for the second round of experiments was 
greater than the first round of experiments, at approximately 0.02-0.2%.  The 
colonies that were selected for expansion satisfied our stringent morphological 
criteria.  These iPS cell lines were all passaged manually at least five times after 
initial isolation, after which the colonies were maintained by enzymatic passage 
using dispase (Invitrogen).   
 
Characterization of pluripotency in second set of iPS cell lines 
We focused on the group of iPS cell lines derived from FAD patients and 
control iPS cell lines for initial characterization by immunostaining for pluripotent 
stem cell markers, Oct4 and Nanog. AD-iPS cells stained positive for Oct4 and 
Nanog (Figure 5A). We then focused on two AD-iPS cell lines, 9908-5 and 6840-
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4, containing mutations in the PSEN2 and PSEN1 genes, respectively, for further 
characterization. 
We first examined their level of expression of pluripotent surface markers.  
Rather than immunostaining to achieve this end, as we had done with the first set 
of iPS cell lines, we used fluorescence activated cell sorting (FACS) analysis, 
which has higher sensitivity and specificity for immunodetection.  FACS analysis 
experiments were performed by the commercial FACS facility at the New York 
Stem Cell Foundation (NYSCF).   
Using FACS analysis, we examined the expression of pluripotent surface 
markers, SSEA-3, SSEA-4 and Tra-1-60 in AD-iPS cell lines 9908-5 and 6840-4.  
The human ES cell line Hues HB9:GFP was used for positive control and both 
fibroblasts and unstained iPS lines were used for negative controls.  AD-iPS lines 
showed low expression levels of all three surface markers.  The mean 
fluorescence intensity for SSEA-3, SSEA-4 and Tra-1-60 in both AD-iPS cell 
lines were about two orders of magnitude lower than that for Hues HB9:GFP (102 
vs. 104).  Additionally, only 0.01% of 9908-5 cells were triple positive, and 0% of 
6840-4 cells were triple positive.  In comparison, about 7.5% of Hues HB9:GFP 
cells were triple positive.  Thus, the level of expression of pluripotent surface 
markers in AD-iPS cell lines were low and the percentage of cells that expressed 
these markers were also low, relative to the Hues HB9:GFP line (Figure 5B). 
To further characterize AD-iPS lines 9908-5 and 6840-4, we used 
quantitative RT-PCR analysis to examine mRNA expression levels of 
pluripotency genes, FoxD3, Tert, Nanog and Cripto.  All mRNA expression levels 
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in AD-iPS cells were normalized to that in Hues HB9:GFP cells.  We found that 
AD-iPS cell lines expressed low levels of pluripotency genes FoxD3, Nanog and 
Cripto.  Nanog and Cripto mRNA levels were negligible; FoxD3 mRNA levels 
were about 60%-75% lower than that in Hues HB9:GFP cells.  However, Tert 
mRNA levels were comparable to that in Hues HB9:GFP cells (Figure 5C, top 
panel). 
We also used quantitative RT-PCR analysis to examine the total mRNA 
expression levels (viral levels plus endogenous levels) and viral mRNA 
expression levels of the four reprogramming factors, Oct4, Sox2, Klf4 and c-Myc.  
The total mRNA levels of Oct4 and Sox2 were negligible.  However, the total 
mRNA levels of Klf4 and c-Myc were about one- to two-fold higher than that in 
Hues HB9:GFP.  Viral mRNA levels of Oct4 and Sox2 were undetectable, 
whereas the viral mRNA levels of Klf4 and c-Myc were substantially higher than 
that in Hues HB9:GFP.  The results of viral mRNA levels are consistent with the 
results of total mRNA levels of the 4 reprogramming factors; for Oct4 and Sox2 
both total and viral mRNA levels are negligible whereas for Klf4 and c-Myc, both 
viral and total mRNA levels are high.  As such, the mRNA levels of Klf4 and c-
Myc is attributable to high gene expression from viral vectors rather than an 
endogenous locus (Figure 5C, bottom panel; Figure 5D). 
Taken as a whole, these experiments show that our second set of iPS 
cells expressed some but not all pluripotency markers. AD-iPS and control-iPS 
cell lines stain positive for Oct4 and Nanog protein (Figure 5A).  Focusing on two 
AD-iPS cell lines, 9908-5 and 6840-4, for further characterization, we found that 
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the expression level of surface pluripotency markers SSEA-3, SSEA-4 and Tra-1-
60 were low in these lines.  Furthermore, while a small percentage of cells in AD-
iPS cell line 9908-5 were positive for all three pluripotent surface markers, no 
cells in AD-iPS cell line 6840-4 were triple positive (Figure 5B).  Examining 
mRNA expression levels of pluripotency markers, we found that Tert mRNA 
expression levels in these lines were comparable to that in human ES cell line, 
Hues HB9:GFP.  However, FoxD3, Cripto, Nanog Oct4 and Sox2 mRNA 
expression levels were low (Figure 5C and 5D).  While the expression levels of 
Klf4 and c-Myc were high, this is attributable to transcription of integrated 
lentiviral vectors rather than gene expression from an endogenous locus.  As 
such, we have partially reprogrammed iPS cells that express some pluripotency 
markers, namely Oct4, Nanog and Tert.      
 
Discussion 
In conducting reprogramming experiments on a large panel of human 
fibroblast cell lines (approximately 20 lines in total), we observed variables that 
consistently affected the efficiency of reprogramming.  One such factor was the 
use of a single polycistronic lentiviral expression vector vs.  multiple 
monocistronic expression vectors for the delivery of reprogramming factors.  
Similar to previous reports (Sommer et al., 2009; Sommer et al., 2010; Carey et 
al., 2009), we found that reprogramming efficiency was increased when we used 
a single polycistronic viral vector compared to multiple individual viral vectors.  
The reprogramming efficiency in our first set of experiments using multiple viral 
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vectors was about 0.01%, whereas the reprogramming efficiency in our second 
set of experiments using a polycistronic vector was about typically about  0.1%.   
Additionally, we found that the growth rate and passage number of 
individual fibroblast cell lines affected their reprogramming efficiency.  Fibroblasts 
lines that had a slower population doubling time generally exhibited lower 
reprogramming efficiency.  Indeed, studies have shown that cell division is 
necessary for reprogramming to occur.  Furthermore, fibroblast cell lines that had 
a higher passage number also exhibited lower reprogramming efficiency.  It is 
possible that sustained maintenance of fibroblasts in tissue culture results in the 
accumulation of subtle changes at the molecular level that affect their capacity to 
be reprogrammed.  This notion is slightly reminiscent of studies that have shown 
that the differentiation status of cells influences their ease for reprogramming.  
For example, hematopoietic stem cells can be more efficiently reprogrammed 
than terminally-differentiated B and T lymphocytes (Eminli et al., 2009).   
When we first set out to generate a patient-specific iPS cell-based model 
of AD, the reprogramming of human somatic cells using iPS cell technology was 
still very much in its infancy.  As such, there was much trouble-shooting involved 
in our first set of fibroblast reprogramming experiments.  That we were not able 
to generate true iPS cells in this first set of experiments is not surprising.  
However, in our second set of experiments, despite our efforts to improve our 
protocol by using a polycistronic vector to increase reprogramming efficiency and 
exercising precision in screening for iPS cell colonies, we nevertheless were 
unable to generate iPS cells that expressed the panel of pluripotency markers 
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necessary for the validation of stemness.  Instead, our iPS cells appear to be 
partially reprogrammed, expressing only some pluripotency markers, namely, 
Oct4, Nanog and Tert.  The most probable explanation for our failure to generate 
fully reprogrammed iPS cells is likely to be the stochastic nature of the 
reprogramming process.  During the course of reprogramming, somatic cells 
become randomly trapped at various stages of de-differentiation, resulting in iPS 
cells that are incompletely reprogrammed (Hanna et al., 2009).   
Studies on the molecular mechanism of reprogramming in mouse somatic 
cells have shown that the de-differentiation of fibroblasts to iPS cells is a 
stochastic process during which cells progress through a series of sequential 
stages to reach pluripotency.  In early reprogramming stages,  AP is activated, 
followed by SSEA-1.  Reactivation of endogenous Nanog and Oct4 occurs late in 
the reprogramming process.  Exogenous viral reprogramming factors need to be 
expressed for about 10-12 days before cells reach a stable pluripotent state 
(Brambrink et al., 2008; Stadtfeld et al., 2008a).   
In the reprogramming of human somatic cells, Chan et al. have found that 
the use of colony morphology to identify potential iPS cells is inadequate (Chan 
et al., 2009).  Many colonies with excellent morphology turned out to be partially 
reprogrammed; one such type of colony expressed neither SSEA-4 nor Tra-1-60 
and another type expressed SSEA-4 but not Tra-1-60.  Curiously, these 
incompletely reprogrammed iPS cells were nevertheless capable of self-renewal 
(Chan et al., 2009).  This capacity for self-renewal is most likely due to 
expression of viral c-Myc.  This oncogene can induce arbitrary self-renewal in 
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many cell types.  Indeed, exclusion of c-Myc from the cocktail of reprogramming 
factors decreases the number of partially reprogrammed colonies (Nakagawa et 
al., 2008; Judson et al., 2009).  
While our AD-iPS cell lines had excellent morphology, they expressed 
only low levels of Oct4, Nanog and Tert and little to no levels of surface markers, 
SSEA-3, SSEA-4 and Tra-1-60.  As such, our iPS cell lines are partially 
reprogrammed, not fully de-differentiated to pluripotent stem cells, but rather, 
suspended in an incompletely de-differentiated state.  The capacity for self-
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Figure 1. AD patient-specific iPS (AD-iPS) cells generated using the viPS 
vector kit (Open Biosystems) display only some markers of pluripotency 
Pluripotency marker analysis of AD-iPS cells (B2-iPS and C8-iPS) and control-
iPS cells. iPS cells were immunostained with antibodies specific to OCT4, 
NANOG, SSEA4, TRA-1-60 and TRA-1-81. Alkaline phosphatase (AP) activity 
was detected using an alkaline phosphatase substrate kit (Vector).  AP and 
OCT4 protein levels are comparable to that of human ES cells (HuES10) (Cowan 
et al, 2004). NANOG levels are low relative to HuES10. SSEA4, TRA-1-60 and 
TRA-1-81 expression was not detected. The morphology of “iPS cell” colonies 
differed from that of human ES cell colonies; “iPS cell” colonies were small, 
irregularly shaped, and had ill-defined boundaries. 








Figure 2. Schematic of the polycistronic lentiviral vector used to derive 
second set of AD patient-specific iPS cell lines (courtesy of  Dr. Rudolph 
Jaenisch) 
The vector contains a cassette consisting of the cDNAs of human Oct4, Klf4, 
Sox2 and cMyc under the control of a constitutive EF1α promoter. An IRES 
element separates two fusion cistrons: (1) Oct4 and Klf4 cDNA fused via self-
cleaving F2A peptide and (2) Sox2 and cMYC cDNA fused via self-cleaving 
peptide E2A.   
	  






	   	  
12 hours 
6 days (change 
medium every 2 days)  
Replace viral medium 
with fresh fibroblast 
cell medium 
Infect fibroblasts with 
OSKM viral supernatant  
every 12 hours over 36 
hours (4 inoculations 
total) 
Re-plate infected 
fibroblasts on MEFs 
1 day  
Replace fibroblast 
medium with human ES 
cell medium  
2-3 weeks (change 
medium every day)  
Screen for iPS cell 
colonies and manually pick  
~1 month (passage  
colonies manually by  
picking every 5-7 days)  
iPS cells were generated using polycistronic KOSM lentiviral vector  
Established iPS cell line 
Figure 3. Schematic outlining the protocol for reprogramming second set 
of AD patient-specific iPS cell lines 
OSKM, lentiviral vector encoding reprogramming factors Oct4, Sox2, Klf4, and 
cMyc; fibroblast cell medium, DMEM supplemented with 10% FBS; human ES 
cell medium, DMEM/F12 with GlutaMAX supplemented with 20% knockout 
serum replacement, 1% nonessential amino acids, 55µM b-mercaptoethanol and 
20 ng/ml bFGF.  
	  

















Figure 4. Second set of AD patient-specific iPS cell lines display 
characteristic human ES cell morphology 
(A) iPS cell lines were generated from familial AD (FAD) and sporadic AD (SAD) 
patient skin fibroblasts obtained from Coriell Insititute.  Familial patient fibroblasts 
contain either presenilin 1 (PSEN1) or presenilin 2 (PSEN2) mutations. 
(B) Representative phase contrast images of iPS cell colonies. Colonies are flat 
and round, with clearly-defined borders.     
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Figure 5A. Second set of AD patient-specific iPS (AD-iPS) cell lines display 
OCT4 and NANOG activity 
Control and AD-iPS cell lines were immunostained for antibodies specific for 
pluripotency markers, OCT4 and NANOG.  iPS cells showed positive 
















Figure 5B. AD patient-specific iPS 
(AD-iPS) cell lines express little to 
no levels pluripotent surface 
markers 
FACS analysis of iPS cells triple-
stained with antibodies specific for 
SSEA-3, SSEA-4 and TRA-1-60.  
The human ES cell line, Hues 
HB9:GFP, was used as a positive 
control.  Unstained iPS cells were 
used as a negative control.   
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Figure 5C. AD patient-specific iPS (AD-iPS) cell lines expressed mostly low 
levels of pluripotency genes 
Quantitative RT-PCR analysis for total mRNA levels of pluripotency genes 
associated with pluripotency, FOXD3, TERT, NANOG, CRIPTO, OCT4, SOX2, 
KLF4 and C-MYC, in AD-iPS cell lines 9908-5 and 6840-4. TERT transcript 
levels were comparable to human ES cells (HuES).  FOXD3, NANOG, CRIPTO, 
OCT4 and SOX2 transcript levels were low to negligible.  KLF4 and C-MYC total 
mRNA levels were about one- to two-fold higher than in HuES. Expression levels 
are normalized to GAPDH; *p<0.05 by ANOVA; n=3 for each line; error bars 
represent the standard error of the mean (SEM). HuES, Hues HB9:GFP cells; 
hFib, human fibroblasts  
	  





















Figure 5D. AD patient-specific iPS (AD-iPS) cell lines expressed high levels 
of viral KLF4 and C-MYC transcripts 
Quantitative RT-PCR analysis for viral mRNA levels of reprogramming factors 
OCT4, SOX2, KLF4 and C-MYC, in AD-iPS cell lines 9908-5 and 6840-4.  
Primers specific for virally encoded transcripts were used.  Viral KLF4 and C-
MYC transcript levels were substantially higher than HuES. Expression of the 
viral OCT4 and SOX2 transgenes was not detectable (plot not shown). These 
results are consistent with analysis of total mRNA levels, which show high total 
levels of KLF4 and C-MYC but extremely low total levels of OCT4 and SOX2 
(Fig.5C). Expression levels are normalized to GAPDH; *p<0.01 by ANOVA; n = 3 
for each line; error bars represent the standard error of the mean (SEM). HuES, 
Hues HB9:GFP cells; hFib, human fibroblasts  
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Chapter 3: Generating an iPS cell-based model of AD to understand cell-
type specificity in AD 
 
Introduction 
The advent of induced pluripotent (iPS) cell technology has spurred great 
excitement in the generation of patient-specific disease models and the need for 
these bioengineered models in studying neurodegenerative diseases is 
irrefutable.  Our aim was to utilize iPS cell technology to generate a patient-
specific iPS cell-based model of Alzheimer’s disease (AD).  While animal models 
of AD have advanced our understanding of its pathophysiology, these models do 
not fully recapitulate aspects of the human disease.  Furthermore, animal models 
and cellular models of AD (based on human cancer cell lines or human 
fibroblasts) do not recapitulate the human intraneuronal environment.  A patient-
specific cell-based model of AD offers a better representation of the intact 
neuronal environment in which the disease arises and as such, may be critical for 
fully elucidating the molecular mechanism of AD. 
At the start of this undertaking, a few proof-of-concept studies had 
previously shown that neurodegenerative diseases can be modeled using iPS 
cell technology, including amyotrophic lateral sclerosis (ALS) (Dimos et al., 2008) 
and spinal muscular atrophy (SMA) (Ebert et al., 2009).  However, an iPS-cell 
based model of AD had not been reported.  We wanted to generate an AD 
patient-specific iPS (AD-iPS) cell-based model of AD that would recapitulate the 
molecular aspects of the disease in a human cellular context.  Dominantly 
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inherited familial forms of AD (FAD) are caused by mutations in APP or in the two 
presenilin genes, presenilin 1 (PSEN1) and presenilin 2 (PSEN2), which encode 
part of the γ-secretase enzyme complex that cleaves APP to Aβ peptides.  At the 
molecular level, these genetic mutations have been shown to affect APP 
processing and Aβ production, resulting in the preferential accumulation of Aβ42 
peptides relative to the Aβ40 isoform  (Shen and Kelleher, 2007; De Strooper 
and Annaert, 2010).  
Furthermore, we wanted to utilize iPS cell technology to examine a key 
feature in AD: cell-type specificity in the manifestation of disease pathology (a 
critical phenomenon common among neurodegenerative diseases).  
Neurodegeneration in AD is largely limited to the medial temporal lobe of the 
cortex and the hippocampus; the major subtype of neurons affected are cortical 
glutamatergic neurons and cholinergic neurons (Khachaturian et al., 1985). The 
mechanism for this selective neuronal loss has been largely unexplored in AD - 
and indeed, among neurodegenerative diseases as a whole - due to the lack of 
molecular tools that would allow for the designing of proper experiments to 
answer this question.  However, iPS technology may prove the contrary and 
potentially offers an excellent platform for studying this phenomenon, as it is 
possible to generate multiple neuron subtypes from disease-specific iPS cells 
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Experimental Design 
The generation of a patient-specific iPS cell-based model of AD involved 
two sequential steps.  The first step was to generate iPS cells from AD patient 
fibroblasts.  Subsequently, these AD patient-derived iPS (AD-iPS) cells were 
differentiated into forebrain cortical glutamatergic neurons.  Furthermore, for 
addressing the question of cell-type specificity in AD, we also differentiated AD-
iPS cells into motor neurons in parallel.  Our strategy was to compare AD-iPS 
cell-derived cortical neurons against AD-iPS cell-derived motor neurons, a 
neuron subtype that is not affected in AD.  We decided to use motor neurons 
because these neurons are unaffected in AD and furthermore, a robust protocol 
exists for the differentiation of human embryonic stem (ES) cells into motor 
neurons (Boulting et al., 2011). 
Our aim was to examine APP processing in the form of Aβ40 and Aβ42 
production in AD-iPS cell-derived cortical neurons and to compare these findings 
against that in AD-iPS cell-derived motor neurons.  Comparison of two neuron 
subtypes generated from the same AD-iPS cell line would allow for good internal 
control when examining differences in molecular and cellular phenotypes. 
 
Results 
Differentiating AD-iPS cells into glutamatergic forebrain neurons  
Our first set of AD-iPS cells, B2-iPS and C8-iPS (see Chapter 2), were not 
able to differentiate into cortical neurons when subjected to a directed 
differentiation protocol for cortical neurons.  We used a protocol that was adapted 
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from Eiraku et al., 2008, which we dubbed the EGF method.  Briefly, iPS cells 
were suspended as embryoid bodies (EBs) in serum-free media. After 25-27 
days in culture, EBs were dissociated and plated on poly-D-ornithine/laminin.  
B2-iPS, C8-iPS and control-iPS differentiation cultures contained cells that 
showed non-specific staining for a pan-neuronal marker, β-III-tubulin (TuJ1), and 
for mature glutamatergic neuron marker, vesicular glutamate transporter-1 
(vGLUT1).  Additionally, differentiated cells did not show characteristic neuronal 
cell bodies or processes (data not shown). 
In differentiating our second set of AD-iPS cells, we focused on three iPS 
lines: 9908-5, which contains the PSEN N141I mutation, 6840-4, which contains 
the PSEN1 A246E mutation and 7871-2, a control line.  Due to difficulty in 
generating neurons with our first set of AD-iPS cells, we decided to experiment 
with two cortical neuron differentiation protocols: our prior EGF method and the 
PALS-C method, which we developed by modifying a motor neuron 
differentiation protocol (Boulting et al., 2011).  We also modified our prior EGF 
method by combining EB formation with active neuralization via dual SMAD 
inhibition with SB431542 and LDN193189 (Boulting et al., 2011).  EBs were then 
treated with EGF and bFGF as before.  In the PALS-C method, EBs were 
actively neuralized but not treated with EGF and bFGF.   
We were able to generate forebrain/telencephalic progenitors from AD-iPS 
cell using both differentiation methods. Forebrain progenitor cells expressed high 
mRNA levels of the forebrain progenitor transcription factor, FOXG1, relative to a 
human fibroblast cell line, as determined by quantitative RT-PCR analysis.  In 
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AD-iPS cell lines 9908-5 and 6840-4, FOXG1 levels in progenitors derived from 
the EGF method was at least half-fold higher than that for the PALS-C method.  
In the control-iPS cell line, 7871-2, the difference in FOXG1 levels for the two 
differentiation methods was not as pronounced (Figure 1A). iPS cell-derived 
forebrain progenitors also stained positive for a dorsal forebrain progenitor 
transcription factor, Pax6.  However, the cells were indistinct and poorly-defined 
compared to telencephalic progenitors derived from human ES line, Hues 
HB9:GFP. Hues HB9:GFP cell-derived progenitor cells formed rosette-like 
structures whereas iPS cell-derived progenitors did not (Figure 1B). 
We found this difference between the EGF and PALS-C methods to be 
carried to the mature neuron stage.   Both protocols were able to generate 
neurons that stained positive for TuJ1 and vGLUT1.  However, cells 
differentiated via the EGF method resulted in neurons with more mature 
branching morphology and strong, stereotypical punctate vGLUT1 
immunostaining whereas neurons derived from the PALS-C method had less 
defined neuronal processes and weak vGLUT1 immunostaining (Figure 2). 
Neurons generated from the EGF method also stained positive for the neocortical 
glutamatergic neuron marker Tbr1, confirming their cortical glutamatergic nature 
(Figure 3). 
The efficiency of neuron differentiation from iPS cells was very low relative 
to Hues HB9:GFP.  In iPS cell lines, the yield of  TuJ1-positive cells ranged from 
0.015% to 0.06%, whereas the yield of TuJ1-positive cells in Hues HB9:GFP 
differentiation cultures was about 24%.  In iPS cell cultures, 33% of Tuj1-positive 
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cells were also positive for vGLUT1.  In HB9:GFP cell cultures 40% of Tuj1-
positive cells were also positive for vGLUT1 (Figure 3).  Given that at the 
progenitor stage, differentiated iPS cell cultures appeared unhealthy, it is not 
surprising that the neuronal yield was so low.  It is possible that cells were 
trapped in the progenitor stage or underwent apoptosis as differentiation 
progressed towards the mature neuron stage.     
 
Differentiating AD-iPS cells into motor neurons  
We differentiated AD-iPS cell lines 9908-6, 6840-4, and control-iPS cell 
line, 7871-2 into motor neurons using  a directed differentiation protocol (Boulting 
et al., 2011).  Briefly, iPS cells were actively neuralized via dual SMAD inhibition 
with drugs SB431542 and LDN193189, and suspended as EBs.  EBs were 
treated with retinoic acid (RA), and purmorphamine, an agonist for the sonic 
hedgehog (SHH) signaling pathway; RA and SHH are CNS regional specification 
factors that induce caudalization and ventralization, respectively.  After 21-22 
days in culture, EBs were dissociated into a single-cell suspension and plated on 
poly-D-ornithine/laminin.  The resulting neurons stained positive for TuJ1, HB9, a 
motor neuron-specific marker (Wichterle et al., 2002), and Islet1, a transcription 
factor involved in motor neuron development (Wichterle et al., 2002; Li et al., 
2005) (Figure 4). 
Similar to cortical neuron differentiation, the efficiency of motor neuron 
differentiation of these iPS cell lines was very low, relative to Hues HB9:GFP.  
The yield of TuJ1-positive cells in iPS differentiation cultures ranged from 0.03% 
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to 0.07%, whereas the yield of TuJ1-positive cells in Hues HB9:GFP 
differentiation cultures was about 6%.  In iPS cell cultures, 25% of Tuj1-positive 
cells were also positive for Islet1.  In HB9:GFP cell cultures 40% of Tuj1-positive 
cells were also positive for Islet1 (Figure 4). 
 
Discussion  
Although we only succeeded in generating partially reprogrammed iPS 
cells, we nevertheless felt it prudent to proceed with neuronal differentiation 
because we had generated a large panel of partially reprogrammed iPS cell lines 
from both FAD and SAD patient fibroblasts.  Indeed, due to their excellent 
morphology, we had high confidence in the pluripotency of our iPS cell lines and 
therefore conducted differentiation experiments in parallel with pluripotency 
validation experiments.  As such, we only became aware of having incompletely 
reprogrammed iPS cell lines after differentiation experiments were well 
underway.  Despite these findings, we resolved to continue our differentiation 
experiments because there was no evidence in the literature that partially 
reprogrammed iPS cells would not be able to differentiate into neurons.  We 
reasoned that it was quite possible that our partially reprogrammed iPS cells 
were dedifferentiated enough for re-direction towards the neuronal lineage.  
Furthermore, because our end goal was to generate a patient-based model of 
AD, whether our original cells were true iPS cells was of little consequence if we 
could succeed in generating forebrain cortical glutamatergic neurons and motor 
neurons from them.  Indeed, we were able to re-direct our partially 
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reprogrammed iPS cells toward the neuronal lineage and succeeded in 
generating both AD-iPS cell-derived forebrain cortical glutamatergic neurons and 
AD-iPS cell-derived motor neurons.  However, differentiation efficiency was low, 
being less than 0.1% for both neuronal subtypes. 
  There is much technical challenge in the differentiation of iPS cell lines.  
Much variation exists among the differentiation efficiencies of iPS cell lines.  
While the overall differentiation efficiency was low among all iPS cell lines, the 
control-iPS cell line 7871-2 consistently yielded higher percentage of neurons, 
followed by AD-iPS line 6840-4 and last, AD-iPS line 9908-5.  This disparity in 
differentiation efficiency has been reported in various other iPS cell studies (Hu 
et al., 2010; Taura et al., 2009; Tokumoto et al., 2010; Boulting et al., 2011). 
Of specific interest, Boulting et al., 2011, reported a comprehensive study 
on a panel of 16 iPS cell lines, examining their pluripotency and ability to 
generate mature motor neurons.  They found variation in the differentiation 
efficiencies among the panel of validated iPS cells lines.  Furthermore, iPS cell 
lines which differentiated poorly into motor neurons could be coaxed into 
differentiation by active neuralization via dual SMAD inhibition using drugs 
SB431542 and LDN193189, the structural analog of dorsomorphin (Chambers et 
al., 2009; Zhou et al, 2010).  SB431542 inhibits endogenous activin/lefty/TGF-β1 
pathways via phosphorylation of ALK4, ALK5, and ALK7 receptors while 
LDN193189 inhibits BMP type I receptors ALK2 and ALK3.  Endogenous BMP 
inhibitors, including noggin (Smith and Harland, 1992; Valenzuela et al., 1995), 
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chordin (Sasai et al., 1994) and follastatin (Hemmati-Brivanlou et al., 1994) are 
known to be critical neural inducing factors.  
That the poorly differentiating iPS cell lines in the Boulting et al., study can 
be coaxed to into differentiation by active neuralization is curious.  Indeed, we 
modified our differentiation protocols to include neuralizing drugs SB431542 and 
LDN193189 after discussions with members of Dr. Christopher Henderson’s lab 
and Project A.L.S.  The rationale for adding these drugs to the differentiation 
protocols was to shorten the amount of time for differentiation and increase 
neuronal yield in the differentiation of true iPS cells (i.e., at the time, we did not 
know we had partially reprogrammed iPS cells in our hands).  However, it may 
be the case that active neuralization was the critical factor that allowed for the 
differentiation of our partially reprogrammed iPS cells into neurons.  One could 
imagine a scenario where our partially reprogrammed cells were in a particular 
dedifferentiated state that when subjected to induction from strong neuralizing 
factors, their cell fate was pushed into the neural lineage.   
Because reprogramming efficiencies were extremely low, we were unable 
to examine APP processing in these cultures, by assaying for secreted Aβ40 and 
Aβ42 using sandwich ELISA.  As such, the validity of our AD-iPS cell based 
















Figure 1. AD-iPS cells can  
differentiate into forebrain 
progenitor cells that 
express markers FOXG1 
and PAX6 
(A) Quantitative RT-PCR 
analysis for  mRNA levels of 
forebrain progenitor 
transcription factor, FOXG1. 
AD-iPS cell lines, 9908-5, 
6840-4 and 7871-2, were 
differentiated using the EGF 
method and PALS-C method 
(see methods chapter). 
FOXG1  levels are 
substantially increased 
relative to human fibroblasts.  
FOXG1 levels in progenitor 
cells derived using the EGF 
method are higher than that 
from the PALS-C method. 
Expression levels are 
normalized to GAPDH; error 
bars represent the standard 
error of the mean (SEM). 
NPC, neural progenitor cells 
(B) Co-immunostain for dorsal 
forebrain progenitor marker, 
PAX6 and general neuronal 
progenitor marker, Nestin. iPS 
cell-derived progenitor cells 
(from AD-iPS cell lines 9908-5 
and 7871-2 differentiated 
using the EGF method) 
express PAX6 but cells were 
indistinct/poorly-defined 
compared to human ES cell-
derived progenitor cells 
(shown here from human ES 
line Hues HB9:GFP). See 
Figure 5  for Pax6 negative 




























Figure 2. AD-iPS cells can  differentiate into mature neurons that express 
TuJ1 and vGLUT1 
iPS cell lines, 9908-5, 6840-4 and 7871-2 were differentiated to cortical neurons 
using the EGF method and PALS-C method (see methods chapter) and co-
immunostained for antibodies specific to panneuronal marker, TuJ1, and mature 
gluatamatergic neuron marker, vGLUT1. Neurons derived from the EGF method 
had more mature branching morphology and strong, punctate immunostaining for 
vGLUT1. Neurons derived from the PALS-C method had less defined neuronal 
processes and weak VGLUT immunostaining. Scale bars, 10um. 
	  













Cell line TuJ1 (%) Tbr1 (% of TuJ1) 
  Hues HB9:GFP 24.1 40 
7871-2 (control) ~0.06 ~33 
6840-4 (PSEN2) ~0.03 ~33 
9908-5 (PSEN1) ~0.15 ~33 
Figure 3. AD-iPS cells can differentiate into glutamatergic forebrain 
neurons 
iPS cell lines, 9908-5, 6840-4 and 7871-2, were differentiated to cortical neurons 
using the EGF method (see methods chapter) and co-immunostained for 
antibodies specific to TuJ1 (a panneuronal marker) and vGLUT1 (mature 
glutamatergic neuron marker) or Tbr1 (neocortical glutamatergic neuron marker). 
iPS cell-derived cortical glutamatergic neurons show co-expression of TuJ1 and 
Tbr1 and of TuJ1 and vGLUT1. The efficiency of cortical neuron differentiation 
from iPS cells is very low, compared to human ES cells (Hues HB9:GFP). Scale 
bars, 10um. (See Figure 6 for Tbr1 control stains).  
	  









 Cell line GFP  TuJ1 (%)  Islet1 (% of TuJ1) 
  Hues HB9:GFP positive 6 39.3 
7871-2 (control) negative ~0.07 ~25 
6840-4 (PSEN2) negative ~0.04 ~25 







Figure 4. AD-iPS cells can differentiate into motor neurons 
iPS cell lines, 9908-5, 6840-4 and 7871-2, were differentiated to motor neurons 
(see methods) and co-immunostained for antibodies specific to TuJ1 (a 
panneuronal marker), and HB9 (a motor neuron marker) or Islet1 (a 
transcription factor involved in motor neuron development). iPS cell-derived 
motor neurons show co-expression of TuJ1 and HB9 and of TuJ1 and Islet1. 
The efficiency of motor neuron differentiation from iPS cells is very low, 
compared to human ES cells (Hues HB9:GFP).  
Scale bars, 10um. 
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Figure 5. Negative control for PAX6 immunostain (Related to Figure 1) 
Human fibroblasts were stained for an antibody specific to Pax6.  DAPI is in blue. 
Negative Pax6 staining is seen here. 
	  
Blovk	  




Figure 6. Postitive and negative controls for TBR1 immunostain (Related to 
Figure 3) 
Primary mouse cortical neurons (top, panel A) and human fibroblasts (bottom,  
panel B) were stained for an antibody specifc to TBR1 (green). DAPI is in blue.  
Primary mouse cortical neuron stain positive for TBR1 whereas human 
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While pluripotent (iPS) cell technology offers an indirect approach to 
neurological disease modeling (generating patient-specific iPS cells and 
subsequent differentiation into neurons), iN cell technology allows for a direct 
approach via the direct conversion of somatic cells to neurons (Figure 1).  Like 
iPS cell technology, iN cellular reprogramming technology has fueled excitement 
for human cell-based modeling of neurodegenerative diseases. 
Because our effort to utilize iPS cell technology to generate a patient-
specific cell-based model of AD was met with tremendous difficulties, we turned 
to iN cell technology as an alternative strategy to achieve our end.  As previous 
studies had shown that neuronal lineage-specific transcription factors can directly 
convert mouse and human fibroblasts to cortical glutamatergic type neurons 
(Vierbuchen et al., 2010; Pang et al., 2011), we reasoned that AD patient 
fibroblast cells could be directly converted to forebrain cortical glutamatergic 
neurons.  In doing so, we would generate a patient-specific cell-based model of 
AD.   
As had been our goal with an iPS cell-based model of AD, we sought to 
generate an iN-cell based model of AD that would recapitulate molecular aspects 
of the disease in a human cellular context.  Our aim was to utilize this iN cell-
based AD model to examine APP processing and Aβ production.   
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Results [All experiments were performed in collaboration. I provided validated 
fibroblast cell lines (those that were able to generate partially reprogrammed iPS 
cells), generated iPS cell-derived neural progenitor cells, and performed controls 
for ELISAs using primary mouse cortical neurons.  Much of the following is 
reproduced from Qiang et al., 2011.]  
 
Reprogramming AD patient fibroblasts to glutamatergic forebrain neurons 
In an initial attempt to generate human induced neuronal (hiN) cells, we 
introduced Brn2, Ascl1, and Myt1, three transcription factors that had been 
shown to be sufficient for reprogramming mouse fibroblast cells (Vierbuchen et 
al., 2010) into the human adult skin fibroblast line STC0022 (isolated from post-
mortem dermal tissue) via lentiviral co-transduction.  This experiment as not 
successful in converting of human fibroblasts to neuronal cells.  Infected cultures 
were unhealthy and apoptotic cell death ensued within a few days of viral 
innoculation.   
Subsequently, lentiviral co-transduction of a larger set of forebrain 
transcription regulators originally identified by Vierbuchen et al., Brn2, Ascl1, and 
Myt1l, Olig2 and Zic1, in the presence of neuronal survival factors brain-derived 
neurotrophic factor (BDNF), neurotrophin-3 (NT3), and glial-conditioned media 
(GCM), allowed for conversion of human adult fibroblasts to hiN cells displaying 
characteristic neuronal morphology (Figures 2A–2N). 
Three weeks after lentiviral transduction, hiN cells were positive for 
neuronal markers, including Tuj1, MAP2, Tau1 and NeuN (Figures 2B–2G and 
	   80	  
2J–2N).  In contrast, fibroblasts transduced with control vectors never gave rise 
to neuronal cells (Figure 2H and 2I).  More than 90% of MAP2-positive cells were 
positive for the neocortical glutamatergic neuron marker Tbr1 (Figure 2K), and 
these Tbr1-positive cells did not express the fibroblast marker, fibroblast-specific 
protein-1 (FSP1; Figure 2L).  Approximately half of the MAP2-positive cells were 
positive for the mature glutamatergic neuron marker vesicular glutamate 
transporter-1 (vGLUT1) in a stereotypical punctate pattern (Figure 2M).  Rare 
MAP2-positive cells (less than 1%) displayed the GABAergic neuron marker, 
glutamic acid decarboxylase-65 (GAD65; Figure 2N). 
We applied our hiN cell conversion protocol to a panel of nine human skin 
fibroblast lines obtained from Coriell: three FAD patient fibroblast lines, three 
SAD patient fibroblast lines and three control fibroblast (Figure 3). The 
conversion efficiency of fibroblasts to MAP2-positive hiN cells across these lines 
ranged from 7.1% to 8.9% (as a percentage of input fibroblasts; n = 3 per group). 
After accounting for cell attrition during the 3-week culture, 28.4%–36.1% of the 
surviving cells were MAP2 positive (Figure 2O).  Across these lines, 48.2%–
60.9% of the MAP2-positive cells were also positive for vGLUT1 (Figure 2P). 
 
Functional Neuronal Properties of hiN Cells 
Electrophysiological characterization of hiN cells 
We assayed the physiological properties of hiN cells via a series of 
electrophysiological studies conducted in collaboration with the lab of Dr. Herman 
Moreno.  Patch-clamp recordings of cells at days 21–28 of culture indicated that 
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the majority of hiN cells displayed typical neuronal Na+, K+, and Ca2+ channel 
properties.  Specifically, TTX-sensitive Na+ currents were characterized by a 
typical current density-voltage relationship (Figures 4A and 4B). Outward 
K+ currents, inhibited in the presence of intracellular cesium (Cs+), were also 
detected (Figures 4C and 4D). Calcium channel function, measured using barium 
(Ba2+) as the charge carrier, displayed typical neuronal characteristics 
(Figure 4E). Consistent with these channel properties, hiN cells were able to fire 
action potentials in response to depolarizing currents (Figure 4F). Furthermore, 
upon termination of hyperpolarizing pulses, hiN cells displayed a typical rebound 
spike (Figure 4F).  The passive membrane properties of hiN cells were also 
consistent with an in vitro neuronal phenotype, with resting membrane potentials 
ranging from −67 mV to −32 mV (average −52 mV; n = 17), membrane time 
constant (τ) ranging from 1.00 to 0.30 ms, membrane resistance (Rm) ranging 
from 0.12 to 1.7 GΩ, and capacitance ranging from 22 to 70 pF.  We further 
evaluated γ-aminobutyric acid (GABA)-ergic and glutamatergic ligand-gated ion 
channel activity in hiN cells.  hiN cells responded to exogenous puff application of 
glutamate or GABA, displaying typical depolarizing and hyperpolarizing currents, 
respectively (Figures 4G–4J). 
 
Integration of hiN cells into neuronal circuitry 
Human iN cells can integrate into neuronal circuitry in vitro and in vivo.  
We did not observe spontaneous activity that is suggestive of neuronal 
connectivity in hiN cells using the standard culture conditions.  We therefore 
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sought to develop alternative protocols that may provide the appropriate 
environmental cues for synaptic maturation.  First, as glial cells can play a major 
role in the regulation of neuronal synaptic development and connectivity (Eroglu 
and Barres; 2010) hiN cells were co-cultured with murine glial cells (obtained 
from mice ubiquitously expressing red fluorescent protein) (Muzumdar et al., 
2007).  After two weeks of co-culture, whole-cell patch-clamp recordings of hiN 
cells (identified as nonfluorescent cells with a neuronal morphology) held at 
−70 mV revealed spontaneous membrane current changes that were sensitive to 
glutamatergic receptor inhibitors, NBQX and APV (Figures 5A-5C; n = 6 of 10 
cells tested). 
Furthermore, GFP-labeled hiN cells were transplanted in utero into 
embryonic day 13.5 mouse brain (Brustle et al., 1997).  The transplanted cells 
migrated from the ventricles into various brain regions, as expected (Figures 5D 
and 5E). The identity of GFP-positive transplanted hiN cells was confirmed by 
immunostaining with an antibody specific for human NCAM (Figure 5F). Voltage-
clamp recordings from GFP-positive hiN cells within acutely prepared brain slices 
from postnatal day 7 pups demonstrated spontaneous currents of various 
amplitudes and frequencies (Figure 5G). These events increased in frequency 
and amplitude upon blockade of GABAA receptors with picrotoxin (Figure 5H) 
and were suppressed with the glutamatergic receptor channel inhibitors NBQX 
and APV (Figure 5I). We confirmed the identity of the recorded cell by dual 
fluorescence imaging (Figures 6A and 6B). Subsequent to the recording, slices 
were immunostained to demonstrate expression of the human-specific 
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mitochondrial marker hMito within recorded cells (Figure 6C). Together, these 
findings support the idea that hiN cells are capable of neuronal connectivity. 
 
hiN Cell Reprogramming is Directed 
Consistent with the idea that the hiN cell phenotype can be achieved 
without neuronal progenitor intermediates, expression of the progenitor markers 
Sox2 and Pax6 was not apparent during hiN cell reprogramming (Figures 7A-7C 
and 7E–7G).  Expression of Nestin, which is associated with neuronal 
progenitors but also functions more generally as a cytoskeleton regulator during 
morphological cell changes (Gilyarov et al., 2008) in a subpopulation of cells 
(<10%; Figures 7I-7K and 7M–7O).  In contrast to hiN cell reprogramming, 
differentiation of human iPS cells to a neural progenitor state led to the robust 
accumulation of Sox2-positive, Pax6-positive, and Nestin-positive progenitors, as 
expected (Figures 7D, 7H, and 7L). RNA expression profiling by real-time 
quantitative RT-PCR similarly indicated that expression of neuronal progenitor 
markers such as FOXG1 and OTX2 was absent from hiN cell culture (Figure 7P).  
 
Analysis of APP processing in AD-iN cells 
We generated hiN cells from a panel of human skin fibroblasts derived 
from familial AD (FAD) patients with  mutations in PSEN1 or PSEN2, sporadic 
AD (SAD) patients, or unaffected individuals (three lines per group). Given the 
likely heterogeneity of sporadic disease and the limited number of samples 
examined in our study, we focused on phenotypic examination of FAD lines.  The 
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general neuronal properties of FAD fibroblast-derived hiN (FAD-iN) cells 
appeared similar to that of control fibroblast-derived hiN (UND-iN) cells, 
 including neuronal reprogramming characteristics, such as efficiency of MAP2-
positive hiN cell generation and the percentage of neurons that express vGLUT1 
(Figures 2O and 2P).  Quantitative RT-PCR analysis revealed that the level of 
expression of the mature neuron marker synaptophysin was comparable among 
the hiN cell cultures (Figure 8A), and cell density at three weeks was not 
significantly different across the hiN cell cultures (Figure 8B). 
 
Increased Aβ42:Aβ40 ratio in FAD-iN cells relative to UND-iN cells and FAD 
fibroblasts 
We evaluated the processing of amyloid precursor protein (APP) to the 
Aβ42 and Aβ40 fragments in the hiN cell cultures.  A key pathological feature in 
FAD patient brain is an increased Aβ42:Aβ40 ratio (Hardy and Selkoe; 2002).  
Consistent with this phenomena, the Aβ42:Aβ40 ratio was dramatically increased 
in FAD-iN cell cultures relative to UND-iN cell cultures, as quantified in cell media 
by ELISA (Figure 9A; p < 0.001, ANOVA with post hoc Tukey HSD; n = 3 patient 
lines per FAD or UND group with 11–16 independent cultures per line).  Similarly, 
on a pooled analysis of all FAD-iN versus all UND-iN cultures, the Aβ42:Aβ40 
ratio is significantly increased in the FAD group (p < 1 × 10−9; ANOVA with post 
hoc Tukey HSD; n > 38 per group).  The increased Aβ42:Aβ40 ratio is most 
evident in the AG07768 line (with mutation in PSEN1), but even in the absence 
of those AG07768 samples, the FAD group displayed an elevated Aβ42:Aβ40 
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ratio (p < 1 × 10−9; ANOVA with post hoc Tukey HSD, n > 29 per group).  
Critically, the Aβ42:Aβ40 ratio in FAD-iN cell cultures was also elevated relative 
to the originating FAD fibroblast cultures (p < 1 × 10−9; ANOVA with post hoc 
Tukey HSD; n > 38 per group).  In contrast, the Aβ42:Aβ40 ratio in UND-iN cell 
cultures was not significantly elevated relative to the originating UND fibroblast 
cultures (p > 0.05; ANOVA with post hoc Tukey HSD; n > 30 per group).   
 
Selective generation of Aβ42 in FAD-iN cells is not attributable to increased 
APP levels 
More than just the Aβ42:Aβ40 ratio, FAD-iN cell conversion led to an 
increase in the total levels of Aβ (combined Aβ42 and Aβ40 polypeptides) 
relative to the originating FAD fibroblasts (Figure 9B; p < 0.05; ANOVA with post 
hoc Tukey HSD; n = 3 individual lines per group, with 11 to 16 independent wells 
for each line).  This increase in total Aβ levels upon AD-iN cell conversion was 
not apparent in UND cultures.  Using co-immunostaining with antibodies to Aβ42, 
Aβ40, and MAP2, we further observed that both isoforms of Aβ are selectively 
increased in the MAP2-positive neuronal cells, but not in the remaining 
fibroblastic cells, that compose the mixed hiN culture (Figures 9C-9F).  Taken 
together, these data indicate that in the context of FAD PSEN-1 and -2 
mutations, fibroblast conversion to induced neuronal cells appears to amplify the 
FAD-associated phenotype. 
Levels of APP holoprotein (the Aβ42 and Aβ40 precursor) did not differ 
significantly between FAD-iN and UND-iN cell cultures, as quantified by ELISA 
	   86	  
on cellular lysates (Figure 9G) and by quantitative RT-PCR on RNA transcripts 
(Figure 9H). However, an increase in APP holoprotein expression was detected 
in both FAD and UND cell cultures in comparison to their originating fibroblast 
cultures.  Because FAD-iN and UND-iN cell cultures displayed similar levels of 
APP, it is unlikely that APP levels account for the selective generation of Aβ42 in 
FAD-iN cells.  
 
Selective generation of Aβ42 in FAD-iN cells is not caused by increased 
BACE1 activity 
Cleavage of APP by BACE1 β-secretase activity is thought to be a rate-
limiting step in the production of Aβ and precedes cleavage by γ-secretase 
(Thinakaran and Koo, 2008).  As such, we quantified the BACE1 cleavage 
product of APP, soluble extracellular sAPPβ, in hiN cell cultures.  The levels of 
sAPPβ were elevated in both FAD-iN and UND-iN cell cultures, relative to their 
respective fibroblasts. However, levels of sAPPβ were comparable between 
FAD-iN and UND-iN cell cultures (Figure 10A).  Additionally, BACE1 transcript 
levels, as determined by quantitative RT-PCR, did not appear altered in all hiN 
cell cultures relative to fibroblasts, regardless of disease status (Figure 10B). 





	   87	  
Discussion 
Recent cellular reprogramming methods are of great utility for human cell-
based disease modeling.  We sought to generate a patient-specific model of AD 
via iPS cell reprogramming.  However,  this strategy was labor intensive and 
wrought with technical challenge.  As such we turned to iN cell reprogramming 
strategy as alternative approach to achieve our end.  Unlike iPS cell 
reprogramming, iN cell reprogramming offered a direct method for generating 
forebrain cortical glutamatergic neurons.  Here we have shown proof-of-principle 
for the utility of iN cell reprogramming technology for human cell-based neuronal 
disease modeling and in particular, for modeling AD.   
Our analysis of FAD patient-derived hiN cell cultures revealed that this iN 
cell-based model of AD recapitulated the key molecular features of AD.  hiN cells 
from PSEN mutant FAD patient fibroblasts display an increased Aβ42:Aβ40 ratio 
relative to UND hiN cells, consistent with patient brain pathology and with the 
well-characterized role of PSENs as essential components of the γ-secretase 
complex (Hardy and Selkoe, 2002).  Surprisingly, the impact of FAD PSEN 
mutations on the Aβ42:Aβ40 ratio was amplified upon hiN cell conversion from 
fibroblasts. This suggests a model in which PSEN FAD mutants may alter APP 
processing at multiple levels: through modified γ-secretase activity, as well as 














Figure 1. Modeling AD using iPS vs. iN cell reprogramming technology _ 
iPS cell technology offers an indirect approach to neurological disease-modeling 
that involves a two-step process: first generating patient-specific iPS cells and 
subsequently differentiating iPS cells into neurons. iN cell technology allows for a 
direct approach to neurological disease-modeling via the direct conversion of 
somatic cells to neurons.   
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Figure 2. hiN Cells Display a Forebrain Glutamatergic Neuron Phenotype 
(A) Schematic of the conversion method. Top panels show phase contrast 
images of human skin fibroblast (left) or hiN cell (right) cultures. TFs, lentiviral 
vectors encoding transcription regulators Ascl1, Brn2, Myt1l, Olig2, and Zic1; 
NTs, neurotrophins BDNF and NT3; GCM, glial-conditioned medium. 
(B–G) Neuronal marker analysis of hiN cell cultures. Human skin fibroblasts (line 
STC0022) were transduced with transcription regulators, cultured for 3 weeks as 
in (A), and subsequently immunostained with antibodies specific to Tuj1 (B and 
E), MAP2 (C), or Tau-1 (F). (D) Merged image of (B) and (C). (G) Merged image 
of (E) and (F). Arrows in (F) indicate the typical distal enrichment pattern of Tau1 
antibody immunostaining.  
(H and I) Absence of neuronal markers in lentiviral vector-only transduced 
fibroblast cultures. Human skin fibroblasts (line STC0022) transduced with 
control lentiviral vector only were analyzed for expression of Tuj1 and MAP2. 
Cultures were counterstained with the nuclear marker DAPI. Neuronal marker 
expression was not detected. 
(J) Costaining of hiN culture with the neuronal nuclear marker NeuN and MAP2 is 
shown. 
(K and L) Forebrain marker expression in hiN cells. The majority of hiN cells 
expressed the neocortical glutamatergic neuron nuclear marker Tbr1 along with 
MAP2. In contrast, Tbr1-positive hiN cells were not stained by the fibroblast 
marker fibroblast-specific protein-1. Arrows in (L) demarcate Tbr1-positive nuclei. 
(M) A majority of Tuj-1-positive hiN cells expressed the glutamatergic neuron 
marker vGLUT1. Inset shows magnified view of the boxed region; arrows indicate 
the typical vGLUT1-positive punctate pattern. 
(N) Only rare (<1%) hiN Tau-1-positive cells also stained positively for GAD65. 
(O and P) Quantification of MAP2- and vGLUT1-positive cells in hiN cell cultures 
derived from a panel of nine human fibroblast lines. (O) Black bars indicate the 
percent of total cells that are MAP2-positive cells with extended processes (at 
least 3-fold greater than soma diameter, as in F). (P) Black bars indicate the 
percent of MAP2-positive cells that stain for the glutamatergic neuron marker 
vGLUT1 as in (M). n = 3 wells for each group; data are presented as mean ± 
SEM.Scale bars: (J) and inset of (M), 10 µm; (B–G), (K–L), and (N), 20 µm; (A), 
(H), (I), and (M), 40 µm 
 
	  






















Table S1. Summary of individual hiN cell cultures and corresponding skin 
fibroblast of origin.  Related to Figure 1.   
All skin fibroblast lines were derived from de-identified, banked tissue samples; 
there was no interaction with subjects, no intervention, and private, identifiable 
information was not collected. STC0022 and STC0033 were obtained from the 
Columbia University Taub Institute New York Brain Bank. Other cultures were 
obtained from Coriell Institute (Camden, NJ, USA) and details are available at 
http://ccr.coriell.org/. Diagnosis is based on clinical diagnosis from Coriell or the 
New York Brain Bank. 
 
































aCulture was derived from spouse of an AD patient, precise age data unavailable. 
Figure 3. Summary of individual hiN cell cultures and corresponding skin 
fibroblasts of origin.  Related to Figure 1.  All skin fibroblast lines were derived 
from de-identified, banked tissue samples.  STC0022 and STC0033 were 
obtained from the Columbia University Taub Institute New York Brain Bank.  
Other cultures were obtained from Coriell Institute (Camden, NJ, USA).  
Diagnosis is based on clinical diagnosis from Coriell or the New York Brain Bank.   
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 Figure 4. Electrophysiological Characterization and Evoked Calcium Transients of Cultured hiN Cells
(A) An example voltage-clamp recording from an hiN cell. Stepping the membrane voltage from!80 mV to more depolarized potentials (!70 to +60 mV in 10 mV
increments) resulted in fast inward currents in 18 of 22 cell analyzed. Shown are example traces between!40 to 0mV. Inset illustrates the pooled current density-
voltage relationship (error bars represent the SEM).
(B) The fast inward currents were sensitive to bath application of the Na+ channel blocker tetrodotoxin (TTX, 600 nM).
(C) Outward K+ currents were obtained (in 14 of the 16 hiN cells recorded) with a KCl-based pipette solution upon depolarizing steps as described above.
(D) Minimal or no outward K+ currents were observed in cells recorded with a Cs+-based pipette solution, as expected, but note the presence of the inward
sodium currents.
(E) Macroscopic whole-cell voltage-dependent Ca2+ channel activity of hiN cells was identified using Ba2+ as the charge carrier. Currents were elicited in
response to depolarizing steps from !70 mV in 10 mV steps (in 3 of the 4 hiN cells analyzed).
(F) In current-clamp mode, hiN cells exhibited a rebound action potential (arrow) at the end of hyperpolarizing current injections and action potentials upon
depolarizing current injection. Bottom panel is a time schematic of the current injection protocol.
(G) Glutamate-mediated postsynaptic currents (PSCs) were elicited by focal application of 1 mM glutamate puffs for 50 ms in cells voltage clamped at !70 mV;
shown are three traces elicited once every 3 min.
(H) Induced PSCs were sensitive to the AMPA channel blocker NBQX (20 mM) and the NMDA blocker APV (50 mM).
(I) Focal application of GABA (50 ms puff, 1 mM) to cells voltage clamped at +20 mV and dialyzed with a low Cl! solution elicited current responses; shown are
three traces evoked every 3 min.
(J) GABA-mediated currents were sensitive to the GABAA antagonist picrotoxin (50 mM). Puff applications of neurotransmitter are indicated by a solid line above
tracings.
(K) (Upper-left) Fluorescence pseudocolor image of a complex axon-like process in an hiN cell dialyzed with 100 mMof the calcium indicator OG-1 (Oregon Green
488 BAPTA-1). (Lower-left) A higher-magnification view of a segment of this process (as demarked by white square in the top panel); individual regions of interest
(ROIs) are indicated by numbered squares within the bottom panel. (Right) Time courses of the relative change in fluorescence (DF/F0) in individual ROIs, as
numbered in the lower-right panel. Calcium transients were evoked by 200ms depolarizing pulses (Vh =!70 to 0mV) in the soma. ROIs #2 and #3 display calcium
transients (hot spots), but no response was elicited in ROI #1.
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Figure 4. Electrophysiological Characterization and Evoked Calcium 
Transients of Cultured hiN Cells 
(A) An example voltage-clamp recording from an hiN cell. Stepping the 
membrane voltage from −80 mV to more depolarized potentials (−70 to +60 mV 
in 10 mV increments) resulted in fast inward currents in 18 of 22 cell analyzed. 
Shown are example traces between −40 to 0 mV. Inset illustrates the pooled 
current density-voltage relationship (error bars represent the SEM). 
(B) The fast inward currents were sensitive to bath application of the Na+ channel 
blocker tetrodotoxin (TTX, 600 nM). 
(C) Outward K+ currents were obtained (in 14 of the 16 hiN cells recorded) with a 
KCl-based pipette solution upon depolarizing steps as described above. 
(D) Minimal or no outward K+ currents were observed in cells recorded with a 
Cs+-based pipette solution, as expected, but note the presence of the inward 
sodium currents. 
(E) Macroscopic whole-cell voltage-dependent Ca2+ channel activity of hiN cells 
was identified using Ba2+ as the charge carrier. Currents were elicited in 
response to depolarizing steps from −70 mV in 10 mV steps (in 3 of the 4 hiN 
cells analyzed). 
(F) In current-clamp mode, hiN cells exhibited a rebound action potential (arrow) 
at the end of hyperpolarizing current injections and action potentials upon 
depolarizing current injection. Bottom panel is a time schematic of the current 
injection protocol. 
(G) Glutamate-mediated postsynaptic currents (PSCs) were elicited by focal 
application of 1 mM glutamate puffs for 50 ms in cells voltage clamped at 
−70 mV; shown are three traces elicited once every 3 min. 
(H) Induced PSCs were sensitive to the AMPA channel blocker NBQX (20 µM) 
and the NMDA blocker APV (50 µM). 
(I) Focal application of GABA (50 ms puff, 1 mM) to cells voltage clamped 
at +20 mV and dialyzed with a low Cl− solution elicited current responses; shown 
are three traces evoked every 3 min. 
(J) GABA-mediated currents were sensitive to the GABAA antagonist picrotoxin 
(50 µM). Puff applications of neurotransmitter are indicated by a solid line above 
tracings. 
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Figure 5. Evidence of hiN Cell Functional Integration 
(A) Representative spontaneous postsynaptic currents recorded from an hiN cell 
present in a murine glial monolayer coculture. The cell was held at −70 mV. 
Events of various amplitudes (5–20 pA) are seen. 
(B) Spontaneous postsynaptic currents as observed in (A) were abolished by 
bath application of NBQX/APV. 
(C) Upon depolarizing current injections in current-clamp mode, action potentials 
were induced. Individual traces represent independent recorded events; action 
potentials (indicated by arrows) were seen in five of the nine tracings. 
(D and E) Confocal fluorescent images of brain slices prepared from postnatal 
day 3 animals that had been grafted in utero with hiN cells. Transplanted hiN 
cells migrated extensively and extended neurite processes. An arrowhead 
indicates cell soma; arrows point to apparent processes. Scale bars: (D) 100 µm, 
(E) 20 µm. 
(F) Confocal reconstruction of a transplanted GFP-positive hiN cell stained with a 
human-specific NCAM antibody. GFP, green; hNCAM, red. Scale bar, 50 µm.( 
G) Voltage-clamp recording of an hiN cell (Vh = −70 mV) integrated into the 
piriform cortex of the host brain, demonstrating spontaneous events of low 
frequency and amplitude. 
(H) The frequency and amplitude of the spontaneous excitatory postsynaptic 
currents (sEPSCs, as in G) increased upon blockade of GABAA receptors with 
50 µM picrotoxin. 
(I) sEPSCs were drastically reduced by blocking glutamatergic synaptic 
transmission with 20 µM NBQX and 50 µM APV. 
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Figure S4. Identification of Transplanted hiN Cells In Vivo, Related to Figure 5
(A) GFP-labeled hiN cells were visualized by fluorescent microscopy within acutely prepared brain slices of P7 to P20 mice after in utero transplantation. A red
fluorescent dye, Alexa-598, was included in the patch recording pipette buffer for facile identification of recorded cells. Fluorescence images are shown using an
excitation wavelength of 470 nm (for GFP; see corresponding cell recording in Figures 5G to 5J). Arrow points to recording pipette.
(B) The red fluorescent dye Alexa-594 was present within the holding pipette solution to allow visual identification of the patched cell. 5 min after whole cell
access, the cell in (A) was re-imaged for red fluorescence (using an excitation wavelength of 590 nM). Arrow points to recording pipette.
(C) Subsequent to electrophysiological recording from the acutely prepared brain slice (as in Figures 5G to 5J), the slice was processed by paraformaldehyde
fixation followed by immunostaining with an antibody for the human-specific mitochondrial antigen (hmito). Multicolor confocal fluorescence imaging confirmed
that the GFP+, Alexa-598+ neuron in (A) and (B) stained positively with the hmito antibody (n = 3).
Cell 146, 359–371, August 5, 2011 ª2011 Elsevier Inc. S11
Figure 6. Identification of Transplanted hiN Cells in Vivo, Related to Figure 
5                                                                                                
(A) GFP-labeled hiN cells were visualized by fluorescent microscopy within 
acutely prepar d brain slices of P7 to P20 mice af er in utero transplantati n. A 
red fluoresce t dye, Alexa-598, was included i  the patch recor i g pipette buff r 
for facile identification of recorded cells. Fluorescense images are shown using 
an excitation wavelength of 470 nm (see corresponding cell recording in Figures 
5G to 5J).  Arrows point to recording pipette.  
(B)The red fluorescent dye Alexa-594 was present within the holding pipette 
solution to allow visual identification of the patched cell. Five munites after whole 
cell access, the cell in (A) was re-imaged for red fluorescence (using an 
excitation wavellength of 590 nM). Arrows point to recording pipette.  
(C) Subsequent to electrophysiological recording from the acutely prepared brain 
slice (as in Figures 5G to 5J), the slice was processed by paraformaldehyde 
fixation followed by immunostaining with an antibody for the human-specific 
mitochondrial antigen (hmito).  Multicolor confocal fluorescence imaging 
confirmed that the GFP-positive, Alexa-598-positive neuron in (A) and (B) stained 
positively with the hmito antibody (n=3).   
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1.7 GU, and capacitance ranging from 22 to 70 pF. We further
evaluated g-aminobutyric acid (GABA)-ergic and glutamatergic
ligand-gated ion channel activity in hiN cells. hiN cells responded
to exogenous puff application of glutamate or GABA, displaying
typical depolarizing and hyperpolarizing currents, respectively
(Figures 4G–4J; 7 of 7 cells analyzed). Finally, to provide func-
tional evidence that hiN cells possess elements of the intrinsic
machinery for synaptic vesicle release, we quantified local
calcium transients within axon-like processes in the context of
membrane step depolarization (using the fluorescent calcium
indicator Oregon Green-BAPTA [OG-1]). Highly localized, depo-
Figure 3. hiN Cell Reprogramming Is Directed
(A–H) Progenitor markers are not detected in hiN cell cultures. Sox2 (A–C)
and Pax6 (E–G) expression were not detected during hiN cell repro-
gramming at 3, 7, and 21 days after transduction. In contrast, human iPSC
cultures differentiated toward a neuroblast stage (IPS-N; D and H) dis-
played prominent intranuclear expression of the factors. Scale bar, 20 mm.
(I–N) Nestin is transiently expressed in a subset of cells within hiN cell
cultures (I–K), albeit less robustly than in iPS-N cells (L). Staining was not
apparent in empty vector-transduced cells (M and N).
(O) Temporal profile of Nestin-positive cells in hiN cell cultures or empty
vector-transduced skin fibroblasts. n = 3 at each time point. *p < 0.05 by
ANOVA with Bonferroni correction. Results represent the mean ± SEM.
(P) Quantitative real-time RT-PCR analysis of neural progenitor marker
gene expression in hiN cell cultures at 0, 7, or 21 days after transduction as
indicated or in iPSC-N cells. Expression levels are normalized to GAPDH;
error bars represent the standard error of themean (SEM); n > 9 per group.
larization-evoked fluorescence intensity changes were
apparent within the axon-like processes of hiN cells (Fig-
ure 4K; seen in 6 of 10 cells), which are thought to represent
putative synaptic release sites (Forti et al., 2000).
hiN Cells Can Integrate into Neuronal Circuitry
In Vitro and In Vivo
Wedid not observe spontaneous activity that is suggestive of
neuronal connectivity in hiN cells voltage clamped at!70mV
using the standard culture conditions as above (n = 16 of 16
cells tested). We therefore sought to develop alternative
protocols that may provide the appropriate environmental
cues for synaptic maturation. First, as glial cells can play
a major role in the regulation of neuronal synaptic develop-
ment and connectivity (Eroglu and Barres, 2010), hiN cells
were cocultured with murine glial cells (obtained from mice
ubiquitously expressing red fluorescent protein) (Muzumdar
et al., 2007). After 2 weeks of coculture, whole-cell patch-
clamp recordings of hiN cells (identified as nonfluorescent
cells with a neuronal morphology) held at !70 mV revealed
spontaneous membrane current changes that were sensitive
to glutamatergic receptor inhibition with NBQX and APV
(Figures 5A–5C; n = 6 of 10 cells tested).
Second, GFP-labeled hiN cells were transplanted in utero
into embryonic day 13.5 mouse brain (Brüstle et al., 1997).
The transplanted cells migrated from the ventricles into
various brain regions, as expected (Figures 5D and 5E and
Table S3). The identity of GFP-positive transplanted hiN cells
was confirmed by immunostaining with an antibody specific
for human NCAM (Figure 5F). Voltage-clamp recordings from
GFP-positive hiN cells within acutely prepared brain slices from
postnatal day 7 pups demonstrated spontaneous currents of
various amplitudes and frequencies (Figure 5G; n = 3). These
events increased in frequency and amplitude upon blockade of
GABAA receptors with picrotoxin (Figure 5H) and were sup-
pressed with the glutamatergic receptor channel inhibitors
NBQX and APV (Figure 5I). We confirmed the identity of the re-
corded cell by dual fluorescence imaging (Figures S4A and
S4B). Subsequent to the recording, slices were immunostained
to demonstrate expression of the human-specific mitochondrial
marker hMito within recorded cells (Figure S4C; n = 3). Together,







	   98	  
 
 
Figure 7. hiN Cell Reprogramming Is Directed 
(A–H) Progenitor markers are not detected in hiN cell cultures. Sox2 (A–C) and 
Pax6 (E–G) expression were not detected during hiN cell reprogramming at 3, 7, 
and 21 days after transduction. In contrast, human iPSC cultures differentiated 
toward a neuroblast stage (IPS-N; D and H) displayed prominent intranuclear 
expression of the factors. Scale bar, 20 µm. 
(I–N) Nestin is transiently expressed in a subset of cells within hiN cell cultures 
(I–K), albeit less robustly than in iPS-N cells (L). Staining was not apparent in 
empty vector-transduced cells (M and N). 
(O) Temporal profile of Nestin-positive cells in hiN cell cultures or empty vector-
transduced skin fibroblasts. n = 3 at each time point. ∗p < 0.05 by ANOVA with 
Bonferroni correction. Results represent the mean ± SEM. 
(P) Quantitative real-time RT-PCR analysis of neural progenitor marker gene 
expression in hiN cell cultures at 0, 7, or 21 days after transduction as indicated 
or in iPSC-N cells. Expression levels are normalized to GAPDH; error bars 
represent the standard error of the mean (SEM); n > 9 per group 
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Figure 8. FAD fibroblast-derived hiN (FAD-iN) and control fibroblast-derived 
hiN (UND-iN) exhibit similar general neuronal properties  
(A) Time course gene expression for synaptophysin in UND and FAD hiN cell 
cultures.  Samples were collected at 0, 1, and 3 weeks after gene transduction 
with the 5 hiN cell conversion factors, as indicated.  Analyses were by 
quantitative RT-PCR.  Expression was comparable in the UND and FAD cultures.  
All data were normalized to GAPDH expression.  p<0.05; n=9.  Results represent 
th mean ± SEM.  
(B) Quantification of average cell number per well in hiN cell cultures at 3 weeks, 
using Hoechst nuclear staining.  Results represent mean ± SEM. 
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Figure 9. Modified APP Processing in FAD hiN Cell Cultures 
(A) The Aβ42:Aβ40 ratio is selectively increased in FAD hiN cell cultures relative 
to UND hiN cell cultures or fibroblasts. Media from hiN cell cultures (at 3 weeks 
post-transduction, empty circles) or fibroblast cultures (green circles), as 
indicated, was assayed for secreted Aβ40 and Aβ42 by sandwich ELISA. Results 
represent the mean ± SEM. n = 3 individual lines per group, with 11 to 16 
independent wells for each line. ∗p < 0.05 by ANOVA with post hoc Tukey HSD 
test.  
(B) Total absolute extracellular Aβ levels (Aβ40 [white bars] + Aβ42 [gray bars]) 
are presented for cultures as in (A). Total Aβ was increased by neuronal hiN cell 
conversion in the context of FAD patient cultures. In contrast, UND fibroblast 
cultures were not significantly different from UND hiN cell cultures. n = 3 
individual lines per group, with 11 to 16 independent wells for each line. ∗p < 
0.05. Results represent the mean ± SEM.  
(C-D) MAP2-positive neuronal cells within the hiN cultures are enriched for the 
Aβ42 and Aβ40 fragment, compared to fibroblastic MAP2-negative cells. FAD 
and UND hiN cell cultures were co-immunostained with antibodies to MAP2 
along with Aβ42 (C) or Aβ40 (D); nuclei are identified by Hoechst staining. 
MAP2-negative fibroblastic cells (demarcated with dotted lines) display low levels 
of Aβ42 and Aβ40 relative to the MAP2-positive cells, as quantified in (E and F).  
(E-F) Aβ42 (F; from C above) and Aβ40 (E; from D above) immunostaining 
fluorescence was quantified within MAP2-positive (‘neuron-like’) and MAP2-
negative (‘fibroblastic’) cells in terms of total Aβ42 (F) or Aβ40 (E) pixel intensity 
per cell using Image J software (NIH). Immunostaining fluorescence pixel 
intensities were quantified for each of the 6 hiN cell cultures (3 FAD and 3UND, 
as per Figure 3); data presented are aggregated into FAD and UND groups. 
Results represent as the mean ± SEM (n = 35-50 cells per well per MAP2-
positive or MAP2-negative group, with 3-4 independent wells per line). ∗p < 0.05. 
(G) Quantification of total intracellular APP holoprotein using sandwich ELISA. 
APP is enriched in hiN cell cultures relative to fibroblast precursors (∗p < 0.05 for 
all comparisons), but UND and FAD genotypes do not differ significantly. Results 
represent the means ± SEM (n = 6–9 wells per group). ∗p < 0.05.  
(H) Time course gene expression for APP in UND and FAD hiN cultures. 
Samples were collected at 0, 1, and 3 weeks after gene transduction with the 5 
hiN cell conversion factors, as indicated. Analyses were by quantitative RT-PCR. 
Expression was comparable in the UND and FAD cultures. All data were 
normalized to GAPDH expression. n = 9. Results represent the mean ± SEM. 
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Figure 10. Modified APP Processing in FAD hiN Cell Cultures: Anaylsis of 
BACE1 Activity  
(A) Accumulation of sAPPβ in the media of UND and FAD cultures, as 
determined by sandwich ELISA. Results represent the means ± SEM; n = 4–5 
wells per individual line. 
(B)Time course gene expression profiles for BACE1 in UND and FAD hiN 
cultures. Samples were collected at 0, 1, and 3 weeks after gene transduction 
with 5 hiN cell conversion factors, as indicated. Analyses were by quantitative 
RT-PCR. Expression was comparable in the UND and FAD cultures. All data 
were normalized to GAPDH expression. n = 9. Results represent the 
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Chapter 5. Summary and Conclusions 
 
Two cellular reprogramming technologies have emerged that demonstrate 
that cell fate can be converted by ectopic expression of defined transcription 
factors: induced pluripotent stem (iPS) cell technology and induced neuronal (iN) 
cell technology.  These recent advances in cell reprogramming strategies have 
great potential utility for patient-specific disease modeling and for applications in 
regenerative medicine. Here we have demonstrated the potential of both iPS and 
iN cellular reprogramming technologies for modeling Alzheimer’s disease (AD).  
These bioengineered human cell-based models of AD provide unique and 
invaluable tools for elucidating the mechanism of AD pathogenesis.   
The generation of an iPS cell-based model of AD involved a two-step 
approach, in which AD-patient specific iPS cells were first derived via direct 
reprogramming of AD patient skin fibroblasts by transcription factors, Oct4, Sox2, 
Klf4 and c-Myc, and then subsequently differentiated into forebrain cortical 
glutamatergic neurons.  One caveat in our results is that we were unable to 
generate true iPS cells that expressed the panel of pluripotency markers 
necessary for the validation of stemness. Rather, our AD-iPS cells were partially 
reprogrammed and only expressed a few pluripotency markers, namely, Oct4, 
Nanog and Tert.  That we were able to generate both motor and cortical neurons 
from these partially reprogrammed iPS cells is curious.  One explanation for this 
result may be our use of neuralizing drugs that mediate dual SMAD inhibition - 
SB431542 and LDN193189, the structural analog of dorsomorphin (Chambers et 
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al., 2009; Zhou et al, 2010) - in our differentiation cultures.  Indeed, in a recent 
study, Boulting et al., have shown that iPS cell lines which differentiated poorly 
into motor neurons could be coaxed into differentiation by active neuralization via 
drugs SB431542 and LDN193189.  It may be the case that active neuralization 
was the critical factor that allowed for the differentiation of our partially 
reprogrammed iPS cells into neurons.  One could imagine a scenario where our 
partially reprogrammed cells were in a particular dedifferentiated state that when 
subjected to induction from strong neuralizing factors, their cell fate was pushed 
into the neural lineage. Because reprogramming efficiencies were extremely low, 
we were unable to examine APP processing in these cultures, by assaying for 
secreted Aβ40 and Aβ42 using sandwich ELISA.  As such, the validity of our AD-
iPS cell based model for AD remains to be determined. 
While we originally sought to generate a patient-specific model of AD via 
iPS cell reprogramming, this strategy proved to be labor intensive and wrought 
with technical challenge.  As such we turned to iN cell reprogramming strategy as 
alternative approach to achieve our end.  Unlike iPS cell reprogramming, iN cell 
reprogramming offered a direct method for generating forebrain cortical 
glutamatergic neurons.  We generated an iN-cell based model of AD by directly 
reprogramming AD patient fibroblast cells to cortical glutamatergic neurons via 
lentiviral expression of lineage-specific conversion factors, Brn2, Ascl1, and 
Myt1l, Olig2 and Zic1 (Vierbuchen et al., 2010). As previous studies had shown 
that neuronal lineage-specific transcription factors can directly convert mouse 
and human fibroblasts to cortical glutamatergic type neurons (Vierbuchen et al., 
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2009; Pang et al., 2011), we reasoned that AD patient fibroblast cells could be 
directly converted to forebrain cortical glutamatergic neurons.  
In generating our AD-iN cell-based model, we have shown proof-of-
principle for the utility of iN cell reprogramming technology for human cell-based 
neuronal disease modeling and in particular, for modeling AD.  Our analysis of 
FAD patient-derived hiN cell cultures revealed that our model recapitulated key 
molecular features of AD.  hiN cells from PSEN mutant FAD patient fibroblasts 
display an increased Aβ42:Aβ40 ratio relative to control hiN cells, consistent with 
patient brain pathology and with the role of PSENs as essential components of 
the γ-secretase complex (Hardy and Selkoe, 2002).  Furthermore, the effect of 
FAD PSEN mutations on the Aβ42:Aβ40 ratio was amplified upon hiN cell 
conversion from fibroblasts. This suggests a model in which PSEN FAD mutants 
may alter APP processing at multiple levels: through modified γ-secretase 
activity, as well as with altered cellular context.   
Bioengineered human cell-based models of AD provide unique and 
invaluable  tools for elucidating the mechanism of AD pathogenesis. Patient-
specific models of AD offer the opportunity to study the disease in a human 
cellular context. Current models of AD, including transgenic animal models do 
not fully recapitulate the AD phenotype. While transgenic models of AD have 
been important tools for understanding the pathophysiological mechanism 
underlying AD, they remain limited in their scope.  Although FAD is linked to 
mutations in APP and PSEN, mutant mice harboring FAD mutations show limited 
representation of the disease profile.  APP mice exhibit only some features of 
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AD, including amyloid plaque formation, synaptic degeneration and memory 
decline.  Furthermore, despite accounting for the overwhelming majority of FAD 
cases, PSEN mutant mice show only accumulation of Aβ42.  While the 3xTg-AD 
mouse model recapitulates many aspects of AD, including NFT pathology, 
amyloid plaque formation, synaptic deficits and memory decline,  MAPT 
mutations are not linked to FAD.  Furthermore, that this aggressive genetic 
approach was necessary to recapitulate salient features of AD speaks to the 
complexity of modeling AD in mice and more importantly, the limitation of the 
mouse system for modeling this human disease (that involves higher cognitive 
function and occurs late in life).   
Previous cellular models for AD have been based on available tissue, 
such as human cancer cell lines and patient fibroblast cell lines, but these 
models cannot recapitulate the unique neuronal environment in which disease 
pathology occur. In this regard, primary neuronal cultures from animal models 
have been used in studies but this approach also has its limitations since these 
models do not fully recapitulate clinical disease phenotypes and are therefore 
limited in their representation of disease pathophysiology.  Indeed, various AD 
animal models have been generated because no one model fully recapitulates 
the human disease.  Compounding this problem is that the same FAD mutation 
modeled in mice with different genetic backgrounds results in different 
phenotypes.  As such, while cellular and animal models have allowed for 
tremendous strides in elucidating the pathogenic mechanisms of AD, our 
understanding of the molecular mechanisms of this disease remains incomplete. 
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In contrast, to mouse models, patient-specific models recapitulate the disease 
within the genetic background of patients.  These models offer the 
unprecedented opportunity for examining disease pathophysiology within the 
human neuronal context and moreover, a patient-specific context. 
Lastly, cell reprogramming-based models of AD may be of great utility for 
modeling sporadic AD.  While FAD mutations have provided a genetic signature 
to model AD, it remains that FAD represents less than 1% of all AD cases.  The 
majority of AD cases are sporadic, with no known genetic links, although studies 
have identified susceptibility genes, including ApoE. As such, cell reprogramming 
strategies may be uniquely positioned to enable the modeling of SAD.  Sporadic 
AD patient-based models may provide answers that can help fill the gaps in our 
knowledge of the disease mechanism of AD.  However, while these models are 
important, much difficulty nevertheless lies ahead in dissecting the mechanisms 
of sporadic AD using these models. 
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Chapter 6. Methods 
 
Cell Culture  
Primary fibroblast lines were obtained from Coriell Cell Repository.  Fibroblasts 
were cultured in fibroblast medium (DMEM supplemented with 10% FBS 
(Invitrogen-Gibco), 1 mM glutamine (Invitrogen). Human ES cells and iPS cells 
were maintained on a feeder layer of mitotically inactivated MEFs plated at 
25,000 cells/cm2 (GlobalStem) in human ES cell medium (DMEM/F12 with 
GlutaMAX supplemented with 20% knockout serum replacement, 1% 
nonessential amino acids, 0.055 mM b-mercaptoethanol (all Invitrogen-Gibco), 
and 20 ng/ml bFGF (Peprotech).  Cells were routinely passaged every 5 to 7 
days with dispase (1 mg/ml) at a dilution of 1:10 to 1:20.   
 
Lentiviral Infection and iPS Cell Derivation 
The protocol used to generate human iPS cells was adapted from established 
protocols (Takahashi et al., 2007; Yu et al., 2007; Park et al., 2008b). VSVg-
coated lentiviral supernatant was generated in 293 FT cells by co-transfection of 
a polycistronic lentiviral vector encoding Oct4, Klf4, Sox2 and c-Myc (Sommer et 
al., 2010) with psPAX2 and pMD2.G (Addgene) into 293 FT cells.  Culture 
medium was changed 12 hr post-transfection, and virus-containing supernatant 
was collected 60–72 hr post-transfection. Viral supernatant was filtered through a 
0.45 µm filter. Fibroblasts were seeded at 1 x 104 cells/cm2 one day before 
infection. Four consecutive infections were performed every 12 hours over a 
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period of 48 hr in the presence of 8 µg/ml of polybrene. Culture medium was 
changed 12 hours after the last infection.  Six days after transduction, fibroblasts 
were passaged using trypsin and re-plated at different densities between  5 × 104 
and 5 × 105 cells/cm2 on MEF feeder layers and cultured in fibroblast medium 
(see above).  Culture medium was replaced by human ES cell medium (see 
above) the following day.  After 2-3 weeks, human iPS cell colonies were picked 
manually based on morphology and manually passaged at least 5 times until a 
stable line was established.   For the first set of iPS cell lines, 4 separate VSVg-
coated lentiviruses were produced for each of 4 reprogramming factors.  Viral 
supernatant was concentrated and pooled for a stock virus.  Fibroblasts were 
infected only once. 
 
Reverse Transcription of Total RNA and Quantitative RT-PCR  
RNA was isolated from fibroblasts, neural progenitor cells, hESCs,  and iPSCs 
using Trizol extraction (hES cells and iPS cells were mechanically separated 
from feeder cells). Reverse transcription was performed on 1µg of total RNA 
using oligo dT priming and the SuperScript III First-Strand Synthesis System for 
RT-PCR (Invitrogen) according to manufacturer’s instructions.  Real-time PCR 
was performed using ABI Prism 7900HT (Applied Biosystems) with Power SYBR 
Green PCR Master Mix (Invitrogen). Gene expression levels were quantified by 
the ΔΔCt method. 
Primers for the analysis of total gene expressions were:  
*OCT4-F: ‘ATGCACAACGAGAGGATTTTGA3’ 




























Gene expression was normalized using GAPDH primers:  
GAPDH-F: 5’GTGAGGGTCTCTCTCTTCCT3’ 
GAPDH-R: 5’GGTCTCCTCTGACTTCAACA3’ 
*From Dimos et al., 2008 
 
FACS Analysis of iPS Cells 
iPS cells were detached using TrypLE Express (Invitrogen). After gentle 
trituration, cells were filtered through cell strainer caps (40 mm mesh) to obtain a 
single cell suspension. Cell were then pelleted by centrifugation at 1000 rpm and 
resuspended in staining buffer (PBS, 0.5% bovine serum albumin [BSA], 2 mM 
EDTA and 20 mM Glucose).  Cell suspensions were incubated with antibodies 
from BD Biosciences: SSEA-3 PE (1:100, 560237), SSEA-4 AlexaFluor647 
(1:100, 560219) and Tra-1-60 AlexaFluor488 (1:100, 560173) for 30 min 
protected from light at 37 deg C. The stained cells were washed twice with 1ml 
staining buffer and again pelleted by centrifugation at 1000 rpm. The pellet was 
resuspended in 400 ml staining buffer. Cells were analyzed using FACS Aria IIu 
(BD Bioscience, CA). SSEA-4+Tra-1-60+ populations were first analyzed by 
forward and side scatter properties (FSC, SSC) then analysis gates were set 
based on fluorescence intensity and negative control.  FACS of iPS cell cultures 
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in the absence of antibody staining (negative control) defined the unstained 
population threshold parameters.  
 
Cortical Neuron Differentiation 
EGF method 
The EGF method was developed by modifying cortical neuron differentiation 
protocol in Eiraku et al., 2008.  Cell colonies were triturated to aggregates of 
about 50 cells in size and seeded in low-adherence dishes at about 300,000 
cells/ml in hES medium (without bFGF).  For the first 3 days, cells were treated 
with 20 µM Y-27632. From days 1-9, cells were treated with SB431542 (10 µM, 
Tocris) and LDN193189 (0.2 µM, Stemgent) to neuralize the cultures.  On day 
12, hES medium was replaced with DMEM/F12 with GlutaMAX supplemented 
with 1x N2 (Invitrogen), 1% nonessential amino acids and 10 ng/ml bFGF 
(Peprotech).  On day 25-27, embryoid bodies were dissociated with 
0.05% trypsin (Invitrogen), and plated onto poly-D-lysine/laminin-coated 24-well 
plates at a density of about 125,000-250,000 cells per well.  The culture medium 
was changed to Neurobasal supplemented with 1x B27, 50 ng/ml BDNF 
(Peprotech) and 50ng/ml NT3 (Peprotech).  Cultures were fixed after 3-4 days.  
 
PALS-C method 
The PALS-C method was developed by modifying the motor neuron 
differentiation (see below) protocol to omit patterning factors specific for motor 
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neurons, namely RA and SAG, caudalizing and ventralizing factors, respectively.  
Additionally, CNTF was not used.   
 
Motor neuron differentiation 
Motor neuron differentiation was performed as described in Boulting et al., 2011.  
iPS cells were treated with dispase (1mg/ml) and mechanically separated from 
feeder cells.  Cell colonies were triturated to aggregates of about 50 cells in size 
and seeded in low-adherence dishes at about 300,000 cells/ml in hES medium 
supplemented with 20 ng/ml of bFGF and 20 µM Y-27632 for the first 3 days. 
From days 1-9, cells were treated with SB431542 (10 µM, Tocris) and 
LDN193189 (0.2 µM, Stemgent) to neuralize the cultures.  At day 4, hES medium 
was replaced with a neural induction medium (NIM; DMEM/F12 with GlutaMAX 
supplemented with 1x N2 supplement (Invitrogen), 1% nonessential amino acids, 
2 µg/ml heparin, and 20 ng/ml bFGF. Starting from day 5, 1µM retinoic acid (RA; 
Sigma), 10 ng/ml BDNF (Peprotech), 0.4 µg/ml ascorbic acid (Sigma) were 
added to the cultures. Starting from day 7, 1 µM smoothened agonist 1.3 (SAG; 
Calbiochem) was added to cultures.  On day 21, embryoid bodies were 
dissociated with 0.05% trypsin (Invitrogen), and plated onto poly-D-
lysine/laminin-coated 24-well plates at a density of about 125,000-250,000 cells 
per well.  The base medium of NIM was changed to Neurobasal (Invitrogen).  All 
factors were maintained and additionally, 25 µM β-mercaptoethanol (Millipore), 
25 µM glutamic acid (Sigma), 1x B27 (Invitrogen) and 10ng/ml each of BDNF, 
GDNF and CNTF (Peprotech) were added.  Cultures were fixed after 2-3 days. 
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Plasmid Construction for hiN 
cDNA of the five reprogramming factors used here–Ascl1, Brn2, Myt1l, Oligo2 
and Zic1–were obtained from Addgene. Inserts were PCR cloned into the 
lentiviral vector construct pLenti6.3/V5-Dest (Invitrogen) by LR clonase reaction 
using standard Gateway Technology cloning techniques (MacLeod et al., 2006). 
To generate a polycistronic vector for expression of Ascl1, Brn2, and Zic1, we 
used a modified pHAGE2-EF1a vector (Sommer et al., 2009). A DNA fragments 
consisting of cDNAs for murine Ascl1 and Brn2, separated by an intervening 
sequence encoding the F2A peptide, was generated by overlapping polymerase 
chain reactions using AccuPrime Taq DNA Polymerase (Invitrogen) as per the 
manufacturer’s instructions. PCRs were carried out using the primer pairs Ascl1 
5’ XbaI/Ascl1-F2A 3’ and F2A-Brn2 5’/ Brn2 3’ Sal1 (see below), and with the 
lentiviral single gene vectors above as substrate. Aliquots of the two purified 
amplicons were then mixed in a 1:1 ratio and used in a second PCR round with 
the primers Ascl1 50 XbaI and Brn2 30 Sal1. The resulting fragment (Ascl1-F2A-
Brn2) was gel-purified and inserted by directional cloning into Xba1 and Sal1-
digested pHAGE2-EF1a-Oct4F2AKlf4- IRES-Sox2E2AcMyc upstream of an 
internal ribosome entry site (IRES) element. Next, a Zic1 cDNA fragment was 
obtained by PCR with primers pairs Zic1 50 NdeI and Zic1 30 ClaI. This fragment 
was then inserted between the NdeI and ClaI sites, downstream of the IRES 
element, of the pHAGE2-Ascl1F2ABrn2 vector. The final construct structure was 
confirmed by sequencing. 
Ascl15’XbaI: CACCGTCTAGAACCATGGAGAGCTCTGGCAAGATGGAGAGTG 
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Ascl1-F2A3’: FCTTGAGAAGGTCAAAATTCAAAGTCTGTTTCACGCCACTT 
CCGTTGAACCAGTTGGTAAAGTCCAGCAGCTC 
F2A-Brn2 5’: AAACAGACTTTGAATTTTGACCTTCTCAAGTTGGCGGGAGA 
CGTGGAGTCCAACCCAGGGCCCATGGCGACCGCAGCGTCTAACCACTA 
Brn2 3’Sal1: TTTGTCGACTCACTGGACGGGCGTCTGCACC 
Zic1 5’NdeI: TGCCATATGATGCTCCTGGACGCCGGA 
Zic1 3’ClaI: GGTTTATCGATTTAAACGTACCATTCGTTAAAATTGGAAGAG 
AGCGCGCTGT  
 
hiN Cell Induction and Transfection  
Fibroblasts were plated at 20,000 cells/well in 24-well plates one day before 
infection and maintained in standard fibroblast media (Dulbecco’s minimal 
essential medium [DMEM] with 10% fetal bovine serum). Culture plates and 
dishes were treated with Poly-L- Ornithine (Sigma) and Laminin (Invitrogen) 
before the application of the cells as per the manufacturer’s instructions. 
Fibroblasts were transduced with replication-incompetent, VSVg-coated lentiviral 
particles encoding Ascl1, Brn2, Myt1l, Oligo2 and Zic1, in fibroblast media 
containing polybrene (8 mg/ml). Each lentiviral type was added at a multiplicity of 
infection 2:1. Two day after transduction, the media was replaced with glial-
conditioned N2 media (GCM; N2 media is DMEM/F12 with N2 supplement; 
Invitrogen) containing 20 ng/ml BDNF and 20 ng/ml NT3 (Peprotech). For glial 
conditioned media, primary cultures of type 1 astroglia were prepared from the 
cortices of P1 rat pups using standard techniques (Kaech and Banker, 2006), 
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and these were subsequently cultured in N2 media for 4 days (Kaech and 
Banker, 2006); media was harvested and filtered through a 45-micron filter 
(Corning) and used immediately. For the first 4 days in N2 media, dorsomorphin 
(1 mM; Stemgent) was applied to the culture. Media was changed every 2-3 days 
for the duration of the culture period.  
 
Immunocytochemistry and Immunohistochemistry 
Cells were fixed in 4% paraformaldehyde for 10 min at room temperature, 
followed by rinsing 3 times with phosphate-buffered saline (PBS). Cells were 
then permeabilized with 0.1% Triton X-100 in 1XPBS for 10 min at room 
temperature. After again rinsing 3 times with PBS, cells were incubated with 
blocking buffer containing 10% goat serum and 10 mg/ml BSA at room 
temperature for 1 hr. All primary antibodies were diluted in PBS. Cells were 
incubated with primary antibodies as listed at 4 deg C for 12-16 hr, followed by 
the corresponding secondary antibody solutions in 37 deg C for 1 hr. Cells were 
rinsed with 1XPBS three times followed by mounting of coverslips with anti-fade 
solution (Invitrogen). Primary antibodies used were (dilutions listed in 
parentheses): OCT4 (1:500 Santa Cruz); SSEA-4 (1:100, DSHB); TRA1-60 
(1:500, Chemicon); TRA1-81 (1:500, Chemicon); Nanog (1:500 R&D); Islet1/2 
(1:100, DSHB); HB9 (1:100 DSHB); mouse anti-Tuj1 (Covance, 1:1000); rabbit 
anti-Tuj1(Covance, 1:2000); rabbit anti-MAP2 (Sigma,1:400); mouse anti-MAP2 
(Sigma, 1:500); mouse anti- Tau (Tau1, Millipore, 1:500); mouse anti-NeuN 
(Millipore, 1:200); rabbit anti-vGLUT1 (Synaptic System, 1:100); rabbit anti-
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GAD65 (Millipore, 1:500); chicken anti-Tbr1 (Millipore, 1:500); mouse anti-human 
neurofilament (Sigma, 1:500); rabbit anti-Pax6 (Millipore, 1:500); mouse anti-
Nestin (Millipore, 1:500); mouse anti-Ascl1 (BD PharMingen, 1:10). Also used 
were: mouse anti-APP (22C11, Milli-pore, 1:500), rabbit anti-APP (KDI, Millipore, 
1:500), rabbit anti-BACE1 (Covance, 1: 500; this was further purified by protein G 
sepharose chromatography kit from GE healthcare), mouse anti-BACE1 (3D5, 
gifts from Robert Vassar), rabbit anti-EEA1 (Millipore, 1:500), mouse anti-M6PR 
(Abcam, 1:500), rabbit anti-LAMP2 (Sigma, 1:400). Dylight 488-, Dylight 549- and 
Dylight 649-conjugated secondary antibodies were purchased from Jackson 
Immunoresearch. Alexa-488, Alexa-633-conjugated secondary antibodies were 
obtained from Invitrogen.  Alkaline phosphatase activity was detected in live 
cultures using the alkaline phosphatase substrate kit (Vector)  according to 
manufacture’s instructions.  
For immunohistochemical analysis of acutely prepared brain sections, the 
following primary anti- bodies were used: rabbit anti-GFP antibody (Invitrogen, 
1:200), mouse anti-human NCAM (Santa Cruz Biotechnology, 1:50), mouse anti-
human mitochondria (hMito, MTC02; Abcam, 1:200). Imaging was performed by 
laser-scanning confocal microscopy with a 63x /1.4 objective (LSM510, Carl 
Zeiss) or by epifluorescence microscope (Olympus 1X71; Japan). hiN cell counts 
and fluorescence intensities were quantified by taking 10 to 35 images of 
randomly selected views per well. Subsequently, images were analyzed for cell 
counts and fluorescent intensity using Image J 1.42q software (National Institute 
of Health, USA). Values are presented as mean ± SEM. 
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FACS Sorting and RNA Extraction for hiN  
hiN cell cultures (106 cells) were detached using TrypLE Express (Invitrogen, 
CA). After gentle trituration, cells were filtered through cell strainer caps (40 mm 
mesh) to obtain a single cell suspension. Cell were then pelleted by 
centrifugation at 1000 rpm and resuspended in 50 ml staining buffer (PBS, 0.5% 
bovine serum albumin [BSA], 2 mM EDTA and 20 mM Glucose). 50 ml antibody 
solution was prepared at 2X concentration (2 ml mouse anti human NCAM 
antibody labeled with a V450 fluorophore [BD Bioscience, CA, 1:50] in 50 ml 
staining buffer). The antibody solution was mixed with the cell suspension in a 
1.5ml eppendorf tube and incubated for 15 min at room temperature. The stained 
cells were washed twice with 1ml staining buffer and again pelleted by 
centrifugation at 1000 rpm. The pellet was resuspended in 400 ml staining buffer 
in a FACS tube (BD Bioscience, CA) and placed on ice.  Cells were analyzed 
using a FACS Aria IIu (BD Bioscience, CA). Gating was based on fluorescence 
intensity of the NCAM-V450 chromophore (at 450 nm) as well as 
autofluorescence (at 660 nm). FACS of hiN cell cultures in the absence of the 
NCAM-V450 antibody (negative control; see S2I) defined the unstained 
population threshold parameters. Subsequently, NCAM-V450 antibody stained 
hiN cells were gated based on these parameters. Cells were sorted directly into 
RNA lysis solution (Ambion, TX) by BD FACS Aria IIu (BD Bioscience, CA).  
 
In Utero Transplantation  
In order to mark transplanted hiN cells, human skin fibroblasts (STC0022) were  
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transduced with a GFP-encoding lentiviral vector 10 days prior to hiN cell 
induction. After three passages to remove contaminating virus, the fibroblasts 
were transduced with lentiviral vectors encoding Ascl1, Brn2, Myt1l, Oligo2 and 
Zic1 as described above. 7 to 10 days after hiN cells induction, hiN cells were 
trypsinized and triturated to single-cell suspensions in the presence of 0.1% 
DNase (QIAGEN). Timed-pregnant C57BL/6N mice at day 13.5 of gestation were 
anesthetized with oxygen containing 2% isoflurane administered through an 
inhalation mask, and 2-5 x105 cells were injected into the telencephalic vesicle of 
each embryo as described (Brustle et al., 1997; Wernig et al., 2008). 
Transplanted mice were spontaneously delivered and analyzed 1 to 2 weeks 
after surgery as indicated. Following deep isoflurane anesthesia, mice were 
decapitated, and the brains were rapidly removed and put in 4% 
paraformaldehyde for two days for fixation. For immunohistochemistry, 50 mm 
sections were cut with a vibrating blade microtome.  
 
Electrophysiology and Calcium Imaging  
Recordings in cultured cells were performed from hiN cells at 3-4 weeks 
after viral infection. Tight-seal whole cell recordings (WCR) were performed with 
borosilicate glass pipettes (resistance 5-8 MU). Recordings were made with an 
Axopatch 200B amplifier (Axon Instruments), and signals were sampled and 
filtered at 10 Khz and 5 Khz, respectively; whole cell capacitance was cancelled 
and S2 Cell 146, 359–371, August 5, 2011 ª2011 Elsevier Inc.series resistance 
compensated 60%–80% using standard techniques. The extracellular solution 
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contained: 140 mM NaCl, 5 mM KCl, 1.5 mM CaCl2, 1 mM MgCl2, 10 mM 
HEPES and 10 mM glucose, pH 7.4 adjusted with NaOH. To study Na+ currents, 
the intracellular solution used was 135 mM CsMeSO4, 4.1 mM MgCl2, 10 mM 
HEPES, 10 mM EGTA, 0.4 mM Na-GTP, 3.6 mM Na-ATP (pH 7.4 adjusted with 
CsOH). To study barium currents the bath solution contained: 132 mM 
tetraethylammonium (TEA)-Cl, 10 mM BaCl2, 10 mM HEPES, and 10mM 
glucose (pH 7.4 adjusted with CsOH). To elicit K+ currents, to view spontaneous 
voltage clamp events, and in the context of glutamate puff and current-clamp 
recordings, the pipette solution had K+ replacing Cs+ as the main cation. GABA 
puff experiments were performed with a lower Cl- intracellular solution, 
approximating physiological levels, as follows: 150 mM Cs-gluconate, 4.6 mM 
MgCl2, 0.1 mM CaCl2, 1 mM EGTA, 10 mM HEPES-Cs, 0.4 mM Na-GTP, and 4 
mM Na-ATP. GABA responses were also elicited using a solution with a Cl- 
concentration close to the extracellular solution (data not shown). Its composition 
was: 150 mM CsCl, 4.6 mM MgCl2, 0.1 mM CaCl2, 1 mM EGTA, 10 mM 
HEPES-Cs, 0.4 mM Na-GTP, and 4 mM Na-ATP, pH 7.4. Liquid junction 
potentials were measured and subtracted for generation of current density-
voltage plots and to measure passive membrane properties. Voltage dependent 
currents were recorded both with and without a P/4 protocol (Bezanilla and 
Armstrong, 1977). Recordings from transplanted cells were performed in acutely 
prepared horizontal and vertical brain slices through the entire cerebrum (180 
mm thick) as described in detail (Llano and Bezanilla, 1980). For glial co-culture 
studies: murine astroglial cells were obtained from mice ubiquitously expressing 
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red fluorescent protein (Muzumdar et al., 2007). Glial cells were prepared as 
previously described (Kaech and Banker, 2006) and added into hiN cultures 
prepared as above, 2 to 2.5 weeks after viral cocktail transduction. 20,000-
25,000 glial cells added/well of a 24-well plate. Recordings from co-cultures were 
performed on cells with a neuronal that lack red fluorescence, 1-2 weeks after 
initiation of co-culturing.  
For recordings from acutely prepared brain slices after in utero 
transplantation: animals were sacrificed at postnatal days as indicated. Brain 
slices were prepared using standard techniques. Recordings were performed at 
20-23! C in GFP-expressing cells identified by fluorescence microscopy. In the 
recording chamber, slices were perfused (1.5 ml/min) with a saline solution 
containing 125 mM NaCl, 2.5 mM KCl, 1.25 mM NaH2PO4, 26 mM NaHCO3, 2 
mM CaCl2, 1 mM MgCl2 and 10 mM glucose equilibrated with a 95% O2-5% 
CO2 mixture. The pipette solution was the same as that used to elicit K+ currents 
above, with the addition of Alexa-598 (Invitrogen) as per the manufacturer’s 
instructions, to allow for visualization of the recorded cells.  
 
Sandwich ELISAs  
APP ELISA was performed using a human APP ELISA kit (Invitrogen, Camarillo, 
CA), according to the manufacturer’s instruction. Absorbance was read on a 
VersaMax ELISA Microplate Reader (Molecular Devices, Inc. Sunnyvale, CA) at 
450 nm. The amount of APP was normalized to the total cell protein (determined 
with the DC Protein Assay Reagent kit; Bio-Rad, Hercules, CA). sAPPb and Ab 
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ELISA were performed on supernatant media from hiN cell cultures at 21 days 
after viral transduction using BetaMark sAPP Beta ELISA kit (Covance, 
Princeton, NJ), according to the manufacturer’s instruction. The 
chemiluminescence was read on a microplate luminometer (SPECTRAFluoR 
Plus, TECAN, Mannedorf Switzerland). Ab quantification was performed by 
ELISA as described previously (Cirrito et al., 2003). Media was conditioned for 48 
hr prior to harvesting. Samples were analyzed for Ab40 or Ab42 using specific 
sandwich ELISAs. Briefly, Ab40, and Ab42 were captured using monoclonal 
antibodies targeted against amino acids 35-40 (HJ2.0), or 33-42 (HJ7.4) of Ab, 
respectively. The antibodies HJ2.0, HJ5.1 and HJ7.4 were gifts from David M. 
Holtzman. For Ab40 and Ab42 assays, a biotinylated central domain monoclonal 
antibody (HJ5.1) followed by streptavidin-poly-HRP-40 was used for detection 
(Sigma). All assays were developed using Super Slow ELISA TMB (Sigma) and 
read on a VersaMax ELISA Microplate Reader (Molecular Devices, Inc. 
Sunnyvale, CA) at 650 nm. ELISA signals were reported as the mean ± SEM of 
three replica wells in ng of Ab per ml supernatant, based on standard curves 
using synthetic Ab40 and Ab42 peptides (rPeptide; Bogart, GA) Samples was 
optimized to detect Ab40 and Ab42 in the ranges of 1-3,000 ng/ml and 0.03–30 
ng/ml, respectively (Figures S5F and S5G). The amount of sAPPb and Ab was 
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